Category: ACN Newswire

HONG KONG, Apr 16, 2026 - (ACN Newswire via SeaPRwire.com) - Sigenergy Technology Co., Ltd. (“Sigenergy” or “the company” Stock Code: 06656.HK) officially commenced trading on the Main Board of the Hong Kong Stock Exchange (HKEX) today. As the first “AI + All-in-One PV Storage” company to list on the exchange, Sigenergy has set a new record for the fastest IPO by a Chinese enterprise.The stock showed strong momentum on its debut, opening at HK$ 581, representing almost an 80% increase over the offer price. Market cap exceeded HK$140 billion. Based on the offer price of HK$324.20 per share, the company raised over HK$4.4 billion in its IPO. If the over-allotment option (greenshoe) is exercised in full, the total proceeds will reach HK$5.06 billion.A Milestone for the Company, the Beginning for a New ChapterFounded only 3 years and 11 months ago, Sigenergy’s rapid path to listing reflects its focus on defining new industry standards rather than following short-term market trends. The IPO attracted a prestigious group of cornerstone investors, highlighting the company’s strategic value in the 2026 Hong Kong market.At the listing ceremony, Mr. Xu Yingtong, Founder and CEO of Sigenergy, together with Mr. Zhang Xianmiao, President of Sigenergy, witnessed this pivotal milestone in the company’s journey.Mr. Xu Yingtong stated: “Listing marks a new beginning for us. Guided by our ‘AI in All’ mission, we are doubling down on energy storage and accelerating R&D to fortify our competitive edge. Our goal is to ensure that AI translates into tangible value for our customers. As we advance our global expansion and refine our international network, we are proud to share the story of ‘China’s Intelligent Manufacturing’ in the renewable energy sector. We promise to uphold the highest standards of operational excellence, rewarding your trust with exceptional results and building a legacy as a transparent, reliable, and socially responsible enterprise.” Sigenergy’s cornerstone investors include world-class sovereign wealth funds and asset managers such as Temasek, Goldman Sachs Asset Management, UBS Asset Management, and BNP Paribas Asset Management. Other notable participants include Hillhouse, CPE, Boyu Capital, Gaoyi Asset Management, and Greenwoods Asset Management, alongside insurance and specialized funds like CPIC, ORIX, and Walden International.This diverse group of high-caliber investors signals a strong market consensus: Sigenergy is recognized as a unique player in the “AI + All-in-One PV Storage” sector, underpinned by proprietary technology, high entry barriers, and predictable growth. Beyond a mere endorsement of the company, this capital influx confirms the market’s conviction that “AI-native” architecture is the definitive standard for next-generation energy storage.Market confidence is supported by Sigenergy’s rapid scale-up. According to the prospectus, the company’s revenue grew from RMB 58.30 million in 2023 to RMB 9.00 billion in 2025, increased 154.4 times in two years. During this period, gross margins expanded from 31.3% to 50.1%, with an adjusted net margin reaching 35.9%. These figures validate the commercial viability of Sigenergy’s “AI-native” technology path.Differentiation Through “AI-Native” TechnologyUnlike traditional “hardware-first, AI-enabled” peers, the company established a more thorough “AI-native” path by integrating artificial intelligence across product design, manufacturing, and business models, the company has achieved a system that is inherently intelligent and capable of continuous evolution.Its flagship product, SigenStor, is a five-in-one system that combines an inverter, EV DC charging module, and battery pack into a modular, stackable unit which achieves a deep integration of power electronics, cloud and AI technologies, enhances product performance while delivering a more convenient user experience.The actual value of system’s “AI-native” capabilities is particularly effective in markets with dynamic electricity pricing. Facing fluctuations on an hourly or even minute-by-minute basis, traditional “charge at low, use at high” strategies based on fixed rules are no longer sufficient. By analyzing real-time prices, weather forecasts, and consumer habits, the system optimizes energy scheduling. In the Swedish market, SigenStor helped users reduce electricity costs by an average of 70.3%, showing the effective translation from AI technology into tangible financial benefits.Sigenergy continuously strengthens its competitive edge through a “Data-Intelligence” closed-loop. As global install base grows, the system leverages real-world operational data to undergo autonomous learning and optimization. This evolution directly translates into superior economic returns for users, which in turn fosters brand loyalty and higher retention. This data-driven cycle creates a powerful network effect, establishing a formidable, long-term barrier to entry in the Energy AI sector.Since its launch, SigenStor has established a strong global presence through its unique value proposition. According to Frost & Sullivan, Sigenergy has become the world No.1 provider of stackable distributed PV and storage all-in-one solutions in 2024, securing a 28.6% market share. Further data from SunWiz confirms that in 2025, the company ranked first in the under-1000kWh segment across Australia, Ireland, and South Africa, while maintaining a top-tier position in the UK, Sweden, and the Netherlands. This deep penetration into high-value markets has delivered significant commercial returns and reinforced Sigenergy’s brand equity. As the company expands into the Asia-Pacific and Latin American regions, its growth trajectory remains robust.To support the trajectory, the company has built a robust manufacturing footprint with production bases in Lingang and Jinqiao, Shanghai, as well as Nantong, Jiangsu. By the end of 2025, the company achieved an annual design capacity of nearly 360,000 inverters and over 5.6 GWh of energy storage batteries. This infrastructure provides a stable foundation for the company’s ongoing global expansion.The successful HKEX listing marks a significant milestone in Sigenergy’s commitment to innovation and recognizes its substantial growth potential. Entering this new chapter, and with the support of premier institutional investors, Sigenergy will focus on optimizing resource integration and accelerating its global ‘AI + Energy Storage’ strategy. By solidifying its technological leadership and market presence, the company aims to build a sustainable foundation for long-term value creation.For inquiries, please contact:EVER BLOOM (HK) COMMUNICATIONS CONSULTANTS GROUP LIMITEDMs. Claire ZhangTel: (852)3468 8171Email: project_alps.list@everbloom.com.cn Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月16日 - (亞太商訊 via SeaPRwire.com) - 4月16日，思格新能源（上海）股份有限公司（以下簡稱「思格新能源」，股票代碼：06656.HK）正式登陸港交所，在成為港股「AI+光儲一體化第一股」的同時，刷新了中國最年輕企業港股IPO最快紀錄，其超額認購近800倍亦創下2026年港股IPO最高認購紀錄，備受全球資本矚目。思格新能源上市首日強勢開盤，開盤價581港元，較發行價上漲80%，市值突破1400億港元。以324.20港元/股的發行價計，公司此次IPO募資規模超44億港元，若計入超額配售權（綠鞋）全額行使，募資總規模達50.6億港元。敲鑼上市，回響未來成立僅3年11個月，思格新能源即成功登陸港交所主板，不僅成為港股上市歷程最快、最年輕的中國企業，更匯聚全球頂級基石投資者，使其成為2026年港股市場基石實力最受矚目的IPO項目。在上市儀式上，思格新能源董事長、CEO許映童先生與公司總裁張先淼先生，共同見證思格新能源發展歷程中最重要的里程碑。許映童先生致辭稱：「上市是新的起點。我們將堅守『AI in All』戰略，深耕儲能領域，加大研發投入，強化技術壁壘，讓AI真正轉化為客戶價值。我們將繼續推進全球化，完善全球網絡，向世界講好中國智造的新能源故事。我們承諾，將以更穩健的經營、更優異的業績，回報每一份信任，努力成為一家讓投資者放心、讓社會認可的公眾公司。」思格新能源此次上市獲得了全球資本的鼎力支持，其基石投資者陣容堪稱「全明星」級別。其中既包括淡馬錫這類全球頂尖主權基金，也涵蓋高盛資產管理、瑞銀資產管理、法國巴黎銀行資產管理等國際一線資管機構，同時匯聚了高瓴、CPE源峰、博裕資本、高毅資產、景林資產等頭部投資機構，以及太平洋保險、富國基金等大型險資，更吸引了歐力士、霸菱、華登國際、蘭馨亞洲、3W Fund等專注不同領域的專業投資方。如此多元且頂級的資本齊聚，共同指向一個清晰共識，即思格新能源被一致視為「AI+新能源」賽道中兼具技術顛覆性、商業高壁壘與成長確定性的稀缺標的。這不僅是對思格新能源的認可，更是資本市場對「AI原生」作為下一代儲能核心形態的絕對信任。資本的青睞，最終需要市場表現來驗證。思格新能源同樣交出了令人滿意的答卷。招股書顯示，2023年至2025年，公司營收從5830.2萬元迅猛增長至90.01億元，兩年增幅高達154.4倍。更令人矚目的是其盈利能力的持續躍升，毛利率從2023年的31.3%大幅提升至2025年的50.1%，同期經調整淨利率達35.9%。思格新能源成功實現了規模與利潤的同步高速增長，印證了其「AI原生」技術路徑所構建的差異化競爭力與商業護城河。極致差異化AI+儲能：從技術重構到生態壁壘的全面領先思格新能源的戰略選擇，自公司創立之初就與行業絕大部分企業截然不同。當多數同行仍遵循「硬件先行，AI賦能」的漸進式疊加邏輯時，思格新能源則確立了一條更為徹底的「AI原生」道路，從產品設計、製造到商業模式，全面融入人工智能，實現系統的智能化和持續進化。公司核心產品SigenStor五合一光儲充一體機，將逆變器、直流充電模塊、儲能電池等多個核心部件高度集成，透過模塊化、可堆疊的設計，實現了電力電子、雲與AI技術的深度融合。不僅提升了產品性能，也為用戶帶來更便捷的使用體驗。在複雜動態電價市場中，SigenStor已驗證了「AI原生」系統的實際價值。面對電價小時級甚至分鐘級的波動，傳統基於固定規則的「低充高放」策略已力不從心。思格新能源的AI系統能夠綜合考慮實時電價、光伏預測和用戶用電習慣，實現智能化調度。在瑞典市場的應用中，該系統幫助用戶平均降低電費70.3%，真正實現了從簡單響應到多因素協同優化的跨越，讓AI技術轉化為用戶的實際收益。思格新能源透過「數據-智能」循環不斷強化自身優勢。隨著設備在全球的部署，系統可基於實際運行數據持續學習優化，提升智能水平。更高的智能水平帶來更優的經濟效益，進而增強用戶口碑與黏性，形成規模效應。這種由數據驅動的循環，正逐漸構建起思格在能源AI領域的長期壁壘。自推出市場以來，SigenStor就憑借獨特價值主張贏得全球認可。據弗若斯特沙利文報告，按產品出貨量計，思格新能源已成為全球排名第一的可堆疊分佈式光儲一體機解決方案提供商，2024年的市場份額高達28.6%。根據SunWiz報告，2025年思格新能源在澳大利亞、愛爾蘭、南非的1000kWh以下系統區間市場份額穩居第一，在英國、瑞典、荷蘭等市場也處於領先地位。在高價值市場的深度滲透，不僅帶來豐厚商業回報，更構築了堅實的品牌壁壘。隨著亞太、拉美等新興市場的拓展，公司增長空間持續擴大。為支撐業務快速發展，思格新能源已構建完善的產能佈局。公司目前在上海臨港、金橋及江蘇南通設有生產基地，截至2025年末，年設計產能達到近36萬台逆變器，儲能電池超5.6吉瓦時，為進一步全球化擴張提供堅實保障。成功登陸港股，是思格新能源以持續創新驅動發展、以高成長性獲得資本市場認可的重要里程碑。此次上市亦標誌著公司邁入全新發展階段。在資本市場支持與優質機構投資者的共同賦能下，思格新能源將進一步強化資源整合能力，加速推進「AI+儲能」戰略的全球化落地，持續鞏固在技術與市場端的領先優勢，穩固長期增長基礎，開拓更廣闊的發展空間。若有垂詢，請聯絡：九富（香港）財訊公關集團有限公司張緣/ Ms. Claire Zhang電話：(852)3468 8171電郵：project_alps.list@everbloom.com.cn Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

台北, 2026年4月16日 - (亞太商訊 via SeaPRwire.com) - OBI Pharma, Inc.（TPEx:4174.TWO）今日宣佈將出席 AACR 2026 年會，並透過十篇海報展示其 GlycOBI® 平台的變革性潛力。傳統 ADC 常因隨機偶聯而受到限制，導致藥物與抗體比值（DAR）不均一、穩定性不足以及治療窗口狹窄。相比之下，OBI 的位點特異性糖鏈技術可實現高度均一的 DAR，從而帶來更優的 PK/PD 特徵，並降低脫靶毒性，這一點已在 OBI 的主要項目 OBI-902 和 OBI-904 中得到驗證。我們正透過新一代雙特異性（OBI-201）以及雙特異性雙載荷（OBI-221）ADC 推動精準腫瘤學的進一步發展。這些“以生物學驅動”的分子旨在克服腫瘤異質性和多藥耐藥性——這是當前癌症治療中的關鍵挑戰。透過結合 GlycOBI® 與 GlycOBI DUO® 平台，OBI 正在開發具有創新性和差異化的療法，以滿足難治性實體瘤患者尚未被滿足的醫療需求。此外，OBI 強大的 ADC 偶聯平台已被證明能夠穩定實現產品品質與可擴展性，同時支援向下一代治療模式拓展，包括降解劑-抗體偶聯物（DAC）。這些數據將於 2026 年 4 月 17 日至 22 日在美國加利福尼亞州聖地亞哥舉行的美國癌症研究協會（AACR）年會上展示。“在 OBI，我們致力於打造更優質的 ADC，”OBI Pharma 首席科學官陳雅琪博士表示。“我們的目標是提供不僅能夠更有效、更精準靶向腫瘤，同時還能減少副作用的療法，為患者帶來具有潛在改變生命意義的治療選擇。”2026年4月20日（星期一）（上午9:00 - 12:00）標題：透過 OBI-902 克服耐藥性：下一代 TROP2 ADC 的臨床前評估1 作者：Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen。OBI Pharma, Inc，台灣台北 會議主題：PO. ET07.01 - 定量藥理學與轉化建模 地點：海報區 17 海報編號：6 摘要編號：1818標題：OBI-904，一種靶向 Nectin-4 的下一代 Exatecan ADC，展現出增強的細胞毒性並克服 Enfortumab Vedotin 耐藥性2作者：Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen。OBI Pharma, Inc，台灣台北會議主題：PO.ET02.02 - 抗體藥物偶聯物與連接子工程 2 地點：海報區 13 海報編號：26 摘要編號：1729標題：OBI-904，一種基於糖鏈的位點特異性靶向 Nectin-4 的 ADC，在非臨床研究中展現出強效且持久的抗腫瘤活性，並具有改進的 PK 特徵及克服 EV 耐藥性的能力3 作者：Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題：PO.ET07.01 - 定量藥理學與轉化建模 地點：海報區 17 海報編號：7 摘要編號：1819標題：具有雙載荷的 MET/HER3 抗體藥物偶聯物：一種消除腫瘤逃逸機制的雙靶點策略5 作者：Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題： PO.CL.0705 - 靶向抗原療法與免疫 地點：海報區 49 海報編號：17 摘要編號：2665標題：引導-效應 bsADC：透過協同內吞作用提升載荷遞送效率6作者：Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題： PO.ET02.02 - 抗體藥物偶聯物與連接子工程 2 地點：海報區 13 海報編號：27 摘要編號：1730標題：親水性增強的連接子技術實現位點特異性的降解劑-抗體偶聯物，具有改進的穩定性和增強的活性7 作者：Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang。OBI Pharma, Inc., 台灣台北會議主題：PO.ET02.02 - 抗體藥物偶聯物與連接子工程 2 地點：海報區 13 海報編號：28 摘要編號：1731標題：基於細胞的載荷釋放揭示雙載荷 ADC 中設計、位點及細胞依賴的比例變化8 作者：Nan-Hsuan Wang, Wei-Han Lee, Evelyn He, Li Chuan Huang, Yu-Chao Huang, David Teng-Yi Huang, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題： PO.CH01.06 - 抗體、抗體藥物偶聯物與核酸 地點：海報區 38 海報編號：5 摘要編號：23972026 年 4 月 20 日（星期一）（下午 2:00 - 5:00）標題：TROP2 上調及其與 HER2 的相互作用介導曲妥珠單抗耐藥性4 作者：Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題：PO.ET03.06 - 藥物耐藥性 1：抗體與 ADC 地點：海報區 12 海報編號：18 摘要編號：29722026 年 4 月 21 日（星期二）（上午 9:00 - 12:00）標題：基於糖鏈的位點特異性 ADC 透過改進的載荷遞送和免疫激活實現持續的腫瘤控制9 作者：Liu Chih-Chun, Tsai Yi-Chien, Huang Jing-Rong, Lo Fei-Yun, Pei Yu, Hsu Ren-Yu, Tu Tzu-Hsuan, Chen Ya-Chi。OBI Pharma, Inc., 台灣台北會議主題： PO.IM02.04 - 癌症中的適應性免疫 地點：海報區 6 海報編號：2 摘要編號：4234標題：透過新一代位點特異性糖鏈偶聯與雙載荷靈活性推進 ADC 治療的發展10 作者：Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang。OBI Pharma, Inc., 台灣台北會議主題： PO.ET02.03 - 抗體藥物偶聯物與連接子工程 3 地點：海報區 12 海報編號：1 摘要編號：4423電子海報將於 4 月 17 日太平洋時間中午 12:00 起在 AACR 虛擬會議平台上線供瀏覽，同時也將於 4 月 18 日起在 OBI Pharma 官網（www.obipharma.com）上線。1 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/45832 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/53853 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/45884 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/50305 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/40516 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/54007 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/54018 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/64749 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/131110 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/5403關於 OBI PharmaOBI Pharma 是一家處於臨床階段的全球腫瘤學公司，成立於 2002 年，總部位於台灣。公司與其子公司 OBI Pharma USA, Inc. 致力於開發創新癌症療法，為具有緊迫醫療需求的患者提供新的治療選擇。OBI 的研究重點是新型抗體藥物偶聯物（ADC）。透過其專有的下一代偶聯技術平台 Obrion™，OBI 建立了多樣化的 ADC 設計模式。該平台整合了專有的偶聯和連接子技術，包括 GlycOBI®、GlycOBI DUO®、EndoSymeOBI®、HYPrOBI®，以及新型不可逆半胱氨酸偶聯技術 ThiOBI®，以推進下一代 ADC 解決方案。OBI 已開發出一系列下一代 ADC 項目，包括單特異性 ADC，如處於 I 期臨床評估階段的 OBI-902（TROP2）和 OBI-904（Nectin-4）；雙特異性單載荷 ADC OBI-201（HER2 × TROP2）；以及雙特異性雙載荷 ADC OBI-221（cMET × HER3）。為拓展 HYPrOBI® 連接子技術的應用範圍，OBI 進一步開發了 ThiOBI® 技術，以實現不可逆的基於半胱氨酸的偶聯。除 ADC 項目外，OBI 的資產還包括 OBI-3424，這是一種類首創的小分子前藥，靶向 AKR1C3，可在醛酮還原酶 1C3 高表達的腫瘤中選擇性釋放強效 DNA 烷化劑。更多資訊請訪問 www.obipharma.com 。關於 OBI-902 和 OBI-992OBI-902 是一種靶向 TROP2 的抗體藥物偶聯物（ADC），攜帶強效拓撲異構酶 I 抑制劑載荷，以藥物-抗體比值（DAR）為 4 殺傷腫瘤細胞。TROP2 在多種實體瘤中高度表達，如乳腺癌、肺癌、膽道癌、膽管癌（膽管細胞癌）、卵巢癌、胃癌等多種癌症類型，因此成為理想的癌症治療靶點。OBI-902 是一種新型位點特異性糖鏈偶聯 ADC，採用 OBI 專有的 GlycOBI® 平台，具有更高的穩定性和更強的親水性。在多種腫瘤模型中（包括非小細胞肺癌、三陰性乳腺癌和胃癌），OBI-902 展現出顯著的抗腫瘤療效、改進的藥代動力學特徵以及良好的安全性。其 IND 已於 2025 年 4 月 30 日獲得美國食品藥品監督管理局（US FDA）批准，並分別於 2025 年 11 月 16 日和 12 月 5 日獲得膽管癌及胃癌（包括胃食管結合部癌）的孤兒藥資格認定。I/II 期臨床試驗（NCT07124117）正在進行中，I 期 a 部分預計於 2027 年上半年完成。OBI-992 是另一種靶向 TROP2 的抗體藥物偶聯物（ADC），透過基於半胱氨酸偶聯的親水性可酶切連接子，以藥物-抗體比值（DAR）為 4 攜帶強效拓撲異構酶 I 抑制劑載荷。OBI-992 在體循環中保持穩定，並將該細胞毒性載荷遞送至表達 TROP2 的腫瘤細胞，從而在避免脫靶毒性的同時實現腫瘤細胞殺傷。OBI-992 的 IND 申請已於 2024 年 1 月獲得美國 FDA 批准，並於 2024 年 8 月獲得用於治療胃癌（包括 GEJC）的孤兒藥資格認定。I/II 期研究（NCT06480240）已達到擬定的 II 期推薦劑量（pRP2D），I 期預計於 2027 年上半年完成。自 2021 年 12 月起，OBI 已獲得 Biosion, Inc.（www.biosion.com）授予的 TROP2 靶向抗體氨基酸序列在除中國大陸、香港和澳門以外所有地區的獨家許可。Biosion 在中國大陸、香港和澳門擁有該抗體序列的獨家權利。OBI 在除中國大陸、香港和澳門以外的所有地區擁有 OBI-992 和 OBI-902 的商業權利，而 Biosion 在中國大陸、香港和澳門擁有相應的商業權利。關於 OBI-904OBI-904 是一種抗體藥物偶聯物（ADC），由特異性靶向 Nectin-4（Nectin 細胞黏附分子 4）的單克隆抗體構成，透過 OBI 專有的 GlycOBI® ADC 賦能技術，並在雙功能酶 EndoSymeOBI® 和新型連接子 HYPrOBI® 的支援下，以藥物-抗體比值（DAR）為 8 偶聯強效拓撲異構酶 I 抑制劑載荷。該藥物有望成為同類首創及同類最佳的基於糖鏈的 ADC，旨在靶向多種表達 Nectin-4 的癌症類型。在多種動物疾病模型中（包括頭頸鱗癌、結直腸癌、三陰性乳腺癌、宮頸癌及肉瘤），其已顯示出抗腫瘤活性；在猴重複給藥毒性研究中，OBI-904 展現出良好的安全性，目前處於 IND 申請前開發階段。關於 OBI-201OBI-201 是一種 TROP2 × HER2 雙特異性 ADC，基於 OBI 的 GlycOBI® ADC 賦能技術構建，並偶聯拓撲異構酶 I 抑制劑。值得注意的是，OBI 首次證明 HER2 與 TROP2 可在細胞表面相互作用並形成蛋白複合物——這一突破性發現得益於與專業 AI 藥物研發合作夥伴的協作。與單特異性 TROP2 或 HER2 ADC 相比，OBI-201 具有多項優勢。透過同時靶向兩種抗原，它可擴大腫瘤覆蓋範圍，尤其適用於靶點表達異質性或表達水平較低的癌症。雙靶向可增強腫瘤選擇性、結合親和力及內吞作用，從而提高載荷向癌細胞的遞送效率，同時有望降低對正常細胞的毒性。OBI-201 還可能克服部分單特異性 ADC 治療後因靶點下調所產生的耐藥性。動物研究表明，在 HER2 表達極低的耐藥性乳腺癌模型中，OBI-201 相較於單靶點 ADC 展現出顯著更優的抗腫瘤活性。OBI-201 能夠持續抑制腫瘤生長，顯示出其克服多種耐藥機制的潛力。OBI-201 是一種新一代雙特異性 ADC，有望突破單靶點 ADC 的局限，為患者提供更全面且持久的治療選擇。關於 OBI-221OBI-221 是一種雙特異性雙載荷 ADC（BsDpADC），基於 OBI 的 GlycOBI DUO® 技術構建，靶向 cMET 和 HER3，並偶聯 MMAE 與拓撲異構酶 I 抑制劑雙載荷。在臨床實踐中，靶向 EGFR 的療法已成為治療非小細胞肺癌（NSCLC）和結直腸癌（CRC）的關鍵策略。然而，腫瘤常透過上調 cMET 和 HER3 快速產生耐藥性，從而維持腫瘤生長。此外，在胃癌、頭頸癌及多種其他實體瘤中也觀察到 cMET 和 HER3 的高表達，進一步凸顯了未被滿足的醫療需求。為應對這一挑戰，OBI Pharma 利用其專有的 GlycOBI DUO® 平台和 HYPrOBI® 連接子開發了新型雙特異性雙載荷抗體藥物偶聯物（BsDpADC）——OBI-221。該治療藥物可同時靶向 cMET 和 HER3，並遞送具有協同作用的細胞毒性載荷，從而有效對抗腫瘤耐藥性和異質性。這一突破性設計不僅滿足未被滿足的醫療需求，也代表了下一代 ADC 開發的前瞻性策略。OBI-221 在克服現有 EGFR 靶向療法耐藥性方面具有重要潛力，有望為患者提供更具針對性的治療選擇，並帶來顯著的臨床價值。關於 GlycOBI®OBI 開發了一種獨特的基於糖鏈的位點特異性 ADC 技術（GlycOBI®），採用即插即用（Plug and Play）設計，可兼容任意抗體、連接子和載荷，並支援多種藥物-抗體比值（DAR）（最高可達 16）。該技術由 OBI 專有的雙功能酶技術 EndoSymeOBI® 和親水性連接子技術 HYPrOBI® 驅動，作為 OBI Obrion™ ADC 技術體系的核心組成部分，能夠在 GMP 條件下透過高效、可規模化、流程簡化的兩步一鍋法偶聯工藝生成位點特異性且高度均一的 ADC。在偶聯過程中，GlycOBI® 避免破壞抗體結構，並確保生成的 ADC 保持與天然抗體相當的生物物理特性。此外，OBI 的連接子技術提高了載荷偶聯效率，並降低了聚集或降解的傾向，從而進一步支援穩定且可控的 ADC 生產過程。GlycOBI® 克服了傳統 ADC 方法常見的局限，並在多項體內研究中展現出更優的抗腫瘤活性和穩定性。值得注意的是，該平台支援偶聯細胞毒性小分子抑制劑以及高度疏水性的降解劑，從而拓展至包括 DAC 在內的下一代治療模式。關於 GlycOBI DUO®GlycOBI DUO® 是一種基於 GlycOBI® 位點特異性偶聯平台及其專有酶促偶聯策略構建的下一代雙載荷抗體藥物偶聯物（ADC）技術。該技術可在單一抗體上以可調比例精確、可編程地連接兩種不同載荷，並支援高 DAR 比值（最高可達 DAR24）。透過結合互補的作用機制，GlycOBI DUO® 旨在增強抗腫瘤療效、應對腫瘤異質性並提升整體治療指數，同時具備克服傳統 ADC 相關耐藥機制的潛力，代表了下一代 ADC 開發的重要進展。關於 ThiOBI®OBI 開發了一種新型不可逆半胱氨酸偶聯 ADC 平台（ThiOBI®），具有更高的穩定性，可適用於任意抗體、連接子和載荷。OBI 專有的 ThiOBI® 平台結合連接子技術（HYPrOBI®），可生成多種生物分子形式的 ADC，包括抗體片段、納米抗體、肽類和蛋白質。此外，OBI 的 HYPrOBI® 連接子技術提高了載荷的偶聯效率，降低了聚集傾向，並延長了 ADC 產品的半衰期。ThiOBI 克服了傳統半胱氨酸 ADC 的局限，並在多項體內研究中實現了更優的抗腫瘤活性和穩定性。GlycOBI®、EndoSymeOBI®、ThiOBI®、HYPrOBI® 和 GlycOBI DUO® 為 OBI 的註冊商標。Obrion™ 為正在申請註冊的商標。前瞻性聲明本新聞稿中非歷史事實的陳述屬於《1995 年私人證券訴訟改革法》所定義的前瞻性聲明。此類前瞻性聲明包括但不限於關於未來臨床試驗、試驗結果及其時間安排的陳述。相關風險因素已在 OBI Pharma 的報告和演示材料中不時披露，包括其向台灣證券期貨局提交的文件。公司聯絡人:Jukka MuhonenExecutive Director, Business DevelopmentOBI Pharma USA, Inc.1.617.821.0292 jukkamuhonen@obipharma.com來源: OBI Pharma USA, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRISBANE, AUS, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology ("G+A CELLS") being developed by GMG and the University of Queensland ("UQ") under a Joint Development Agreement with Rio Tinto, one of the world's largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana ("BIC") in the United States of America.The GMG G+A CELLS have now demonstrated superior performance characteristics when compared to a representative market leading ultra-fast charging batteries, the Lithium Titanate Oxide ("LTO") batteries, which can be sold at a premium price of up to US$1200/kWh.1Figure 1 shows the current energy density of G+A CELLS, based on BIC testing, and shows the doubling in performance (26 to 49 Wh/kg) since the previous announcement in December 20252 and in comparison, to a representative market leading fast charging high power LTO batteries.Figure 1: Increase in Energy Density for G+A CELLS since December '25 UpdateTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure1.jpgFigure 2 shows the charge and discharge curves for the G+A CELLS when charged in 6 minutes (10C) and 60 minutes (1C). The energy density of the cells for the G+A CELLS when charged in 60 minutes (1C) is now 101 Wh/kg when charging to 100% State of Charge (SOC) which is an increase from 58 Wh/kg from the previous update. This shows the G+A CELLS have a nominal voltage of approximately 3.2 Volts (an increase from 3.0 Volts in the previous update). The G+A CELLS maintained performance over hundreds of cycles at 6-minute fast charging rate (10C).Figure 2: Battery performance curves of G+A CELLS at 60 min and 6min charge (1C & 10C)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_001full.jpgBob Galyen, GMG Non-Executive Director and former CTO of CATL - the largest battery manufacturer in the world, commented: "With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG's battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems and or combinatorial systems with multiple battery technologies while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells - it is a new platform that can open markets and use cases that were previously uneconomic or impractical. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology."Standard commercial Lithium Nickel Manganese Cobalt ("LNMC") and Lithium Iron Phosphate ("LFP") battery cells for electric vehicles and stationary storage are NOT designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).3GMG has now developed a completely new hybrid electrolyte that is chloride free and non-corrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over hundreds of cycles. The substrate for both the cathode and anode in the G+A CELLS is aluminium foil - which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG's technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.GMG believes that it has significantly met the key target specification requirements for use in heavy mobile equipment, as shown in Figure 3, its main targeted use case, including:- Charging in under 6 minutes;- Energy density > 100 Wh/kg after 1 hour of charging; and- Safe (no Lithium).The next battery development steps include the following activities:- Test and show cycle life up to 10,000 cycles- Test and show ambient temperature impacts- Test and show standard safety testing- Test and show no thermal battery management system needed Figure 3: G+A CELLS Battery Use Case - heavy mobile equipmentTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure3.jpgCraig Nicol, GMG Managing Director and CEO, commented: "This is a significant step up from where we were at with battery performance in December 2025 and we see the required performance for our targeted use case being largely met - which means we can start to put together the next stages of the battery maturation program - including partnerships and manufacturing plans."GMG management believes that the G+A CELLS can eventually achieve over 160 Wh/kg when charged in 1 hour, and over 80 Wh/kg when charged in 6 minutes with further development of the cathode, anode, electrolyte and component weights.Figure 4 shows the latest G+A CELLS in pouch format:Figure 4: Current Multi-Layer G+A CELLTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure4.jpgBattery Technology Readiness LevelThe battery technology readiness level ("BTRL") of the G+A CELLS remains at Level 4, whilst significantly progressed through this level as shown in Figure 5. GMG is currently in the process of completing the optimization of the electrochemical behaviour for the pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will ultimately progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+A CELLS are the same as those employed to make Lithium-Ion Batteries, though no definitive timeline for achievement can be provided at this time.Figure 5: Battery Technology Readiness Level (BTRL)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_004full.jpgThe Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.Figure 6: Battery Cell RoadmapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_005full.jpgNext Steps Toward Commercialisation & Market ApplicationsJack Perkowski, GMG Non-Executive Chairman and Director, commented: "I am extremely proud that GMG has progressed its battery to this stage - the Company is getting very close to final commercialisation steps. We look forward to providing further updates as GMG progresses the development of its battery technology."The Company continues to see a broad range of potential applications for a completed G+A CELLS - utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:Figure 7: Market ApplicationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_006full.jpgCurrently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells - reducing the weight, cost and complexity relative to using a metal case. Using a plastic battery pack is possible for two main reasons - GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of G+A CELL packs when compared to lithium-ion batteries.Figure 8: Expected Battery Pack for GMG's G+A CELLS Pouch FormatTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_007full.jpgComparison and Market Review: LTO Batteries As shown in Figure 9 below, the performance of GMG's G+A CELL technology is already very similar to representative LTO batteries.Figure 9: Comparison of GMG's G+A CELLS to Lithium Titanate Oxide (LTO) BatteryTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure9.jpg LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for G+A CELLS are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.LTO batteries have energy density ranging from 50 - 80 Wh/kg.6 The LTO product is sold globally for use in many applications — with a total of US$5.67 billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 16.9% per annum to an estimated US$ 12.5 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+A CELLS can be substituted at a substantially lower cost.Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power "opportunity charges" during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 °C to +60 °C ambient.5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.12V starter replacement to Lead acid: GMG's G+A CELLS battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry's stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe's Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries' fast-response profile.Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.Summary of Important Milestones for GMG's G+A CELLS Development: MonthImportant Milestones in the Development of the Graphene Aluminium Ion BatteryMay 2020GMG and UQ win Australian Research Council grant for Graphene battery developmenthttps://graphenemg.com/gmg-and-uq-wins-australian-research-council-grant-for-graphene-aluminium-ion-battery-development/Apr 2021The University of Queensland and GMG kick off coin cell battery development projecthttps://graphenemg.com/gmg-the-university-of-queensland-research-uni-quest-kick-off-the-graphene-enhanced-aluminium-ion-battery-development-project/May 2021Graphene aluminium-ion battery performance data - Energy Density and Power Densityhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-performance-data/Jun 2021Graphene aluminium-ion battery performance data - Cycle Lifehttps://graphenemg.com/graphene-aluminium-ion-battery-performance-data/Jun 2021Significant potential battery customer market response to launch of batteryhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-progress-update/Jul 2021Investment decision for coin cell battery development centrehttps://graphenemg.com/gmg-battery-pilot-plant-investment/Oct 2021Construction starts for coin cell battery development centrehttps://graphenemg.com/construction-battery-pilotplant/Oct 2021Bosch Australia Manufacturing Solutions and GMG sign Letter of Intenthttps://graphenemg.com/gmg-and-bosch-sign-collaboration-arrangement-for-bosch-to-design-and-deliver-gmgs-graphene-aluminium-ion-battery-manufacturing-plant/Dec 2021Commencement coin cell battery development centrehttps://graphenemg.com/battery-pilot-plant/Dec 2021Initial coin cell batteries sent for customer feedbackhttps://graphenemg.com/graphene-aluminium-battery-customers-prototypes/Mar 2022Initial factory acceptance testing of semi-automated prototype battery cell assembly equipmenthttps://graphenemg.com/gmg-announces-initial-factory-acceptance-testing-of-semi-automated-prototype-battery-cell-assembly-equipment/Mar 2022Wood Engineering and GMG Sign a Letter of Intenthttps://graphenemg.com/gmg-and-wood-agree-collaboration-arrangement-for-wood-to-engineer-and-deliver-major-graphene-manufacturing-expansion-projects/May 2022Rio Tinto and GMG sign Letter of Intenthttps://graphenemg.com/gmg-riotinto-energysavings-battery/Jun 2022Commissioning of Pouch Cell Equipmenthttps://graphenemg.com/gmg-manufactures-first-pouch-cell/Jun 2022Bob Galyen, former chief technology officer of CATL, joins GMG technical advisory committee.https://graphenemg.com/gmg-technical-advisory-committee-leadership-team-additions-and-cfo-change/Aug 2022Investment decision for Phase 1 modular Graphene Production Planthttps://graphenemg.com/gmg-announces-phase-1-expansion-project-to-graphene-manufacturing-facility-for-energy-saving-products-and-batteries/Oct 2022Significant battery performance, cell and graphene production improvementshttps://graphenemg.com/gmgs-battery-update-significant-battery-performance-cell-and-graphene-production-improvements/Dec 2022Investment of $600k Battery Development Centrehttps://graphenemg.com/gmg-invests-au-600000-to-accelerate-battery-pouch-cell-customer-testing-development-in-2023/Feb 2023Australian Government Approval (AICIS) for production and sale of batteries.https://graphenemg.com/gmg-receives-regulatory-approval-to-enable-significant-commercial-sales/May 2023Battery Joint Development Agreement with Rio Tinto signedhttps://graphenemg.com/gmg-announces-battery-joint-development-agreement-with-rio-tinto/May 2023Battery Technology Readiness Level (BRTL) 2-3 reachedhttps://graphenemg.com/gmg-announces-battery-team-and-related-updates/May 2023Decision to switch to develop Pouch Cells (instead of Coin Cells)https://graphenemg.com/gmg-announces-battery-team-and-related-updates/Jul 2023Bob Galyen former chief technology officer of CATL joins GMG board of Directorshttps://graphenemg.com/graphene-manufacturing-group-appoints-former-chief-technology-officer-of-catl-limited-to-its-board-of-directors/Sep 2023Battery Pouch Cell Prototypes Multilayered Auto-Stacker Demonstrationhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-pouch-cell-prototypes-multilayered-auto-stacker-demonstration/Sep 2023Reaching 500 mAh capacity batteryhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Sep 2023Battery Technology Readiness Level (BRTL) 4 reachedhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Nov 2023Rio Tinto and GMG Partnership Video Launchedhttps://graphenemg.com/rio-tinto-gmg-battery-partnership-video-launch/Dec 2023Commissioning of modular Graphene Production Planthttps://graphenemg.com/graphene-manufacturing-group-commissions-modular-graphene-production-plant/Feb 20241000 mAh Capacity Reachedhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-1000-mah-capacity-reached-and-next-steps-toward-commercialisation/Mar 2024Graphene Manufacturing Group Secures AU$2 million Funding Grant from Queensland Government for Battery Pilot Planthttps://graphenemg.com/graphene-manufacturing-group-secures-au2-million-funding-grant-from-queensland-government-for-battery-pilot-plant/Aug 2024GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-progress-update-and-next-steps-toward-commercialisation/Mar 2025GMG's Graphene Aluminium-Ion Battery: Collaboration with World Leading USA Battery Innovation Centre and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-collaboration-with-world-leading-usa-battery-innovation-centre-and-next-steps-toward-commercialisation/Dec 2025GMG Unveils Graphene Aluminium-Ion Battery that Fully Charges in 6 minuteshttps://graphenemg.com/gmg-unveils-graphene-aluminium-ion-battery-that-fully-charges-in-6-minutes/ About BIC:BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041www.graphenemg.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the pricing of LTO batteries, expectations for GMG G+AI batteries to achieve specification requirements for heavy mobile equipment, the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, stability, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 04, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.1 https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.2 https://graphenemg.com/gmg-unveils-graphene-aluminium-ion-battery-that-fully-charges-in-6-minutes/3 https://findingspress.org/article/21459-impact-of-charging-rates-on-electric-vehicle-batt4 High-power type cells | SCiB™ Rechargeable battery | Toshiba5 https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.6 https://www.grepow.com/blog/battery-energy-density.html7 Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends ReportTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/292641 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAIPEI, TW, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904.We are further advancing precision oncology through our next-generation bispecific (OBI-201) and bispecific, dual-payload (OBI-221) ADCs. These "biology - driven" molecules are designed to overcome tumor heterogeneity and multi-drug resistance-key challenges in current cancer treatment. By incorporating both the GlycOBI® and GlycOBI DUO® platforms, OBI is developing novel and differentiated therapeutics addressing the unmet medical need for patients with difficult-to-treat solid tumors. Additionally, OBI's robust ADC conjugation platform has proven to consistently deliver product quality and scalability, while enabling expansion into next-generation modalities, including degrader-antibody conjugates (DACs).These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 17 to 22, 2026 in San Diego, CA. (USA)."At OBI, we make better ADCs," said Dr. Ya-Chi Chen, Chief Scientific Officer OBI Pharma. "Our goal is to deliver therapies that not only target tumors more effectively and precisely, but also reduce side effects, giving patients potentially life-changing treatment options."Monday, April 20, 2026 (9:00 AM - 12:00 PM)Title: Overcoming Resistance with OBI-902: Preclinical Evaluation of a Next-Generation TROP2 ADC1Authors: Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO. ET07.01 - Quantitative Pharmacology and Translational ModelingLocation: Poster Section 17Poster Board Number: 6Abstract Presentation Number: 1818Title: OBI-904, a Next-Generation Nectin-4-Targeting Exatecan ADC, Demonstrates Enhanced Cytotoxicity and Overcomes Enfortumab Vedotin Resistance2Authors :Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number: 26Abstract Presentation Number: 1729Title: OBI-904, a Glycan-based Site specific Nectin-4-Targeted ADC, Demonstrates Potent and Durable Antitumor Activity with an Improved PK Profile and Overcoming EV-Resistance in Non-Clinical Studies3Authors: Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET07.01 - Quantitative Pharmacology and Translational ModelingLocation: Poster Section 17Poster Board Number: 7Abstract Presentation Number: 1819Title: The MET/HER3 Antibody-Drug Conjugate with Dual Payload: A Dual-Target Approach to Eliminate Tumor Escape Mechanisms5Authors: Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.CL.0705 - Targeted Antigen Therapies and ImmunityLocation: Poster Section 49Poster Board Number: 17Abstract Presentation Number: 2665Title: Guide-effector bsADCs: Driving co-endocytosis for enhanced payload delivery6Authors: Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen .OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number : 27Abstract Presentation Number: 1730Title: Hydrophilicity-Enhanced Linker Technology Enables Site-Specific Degrader-Antibody Conjugates with Improved Stability and Enhanced Activity7Authors: Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number: 28Abstract Presentation Number: 1731Title: Cell-based payload release highlights design, site, and cell-dependent ratio shifts in dual-payload ADCs8Authors: Nan-Hsuan Wang, Wei-Han Lee, Evelyn He, Li Chuan Huang, Yu-Chao Huang, David Teng-Yi Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.CH01.06 - Antibodies, Antibody-Drug Conjugates, and Nucleic AcidsLocation: Poster Section 38Poster Board Number: 5Abstract Presentation Number: 2397Monday, April 20, 2026 (2:00 PM - 5:00 PM)Title:TROP2 Upregulation and Interaction with HER2 Mediate Trastuzumab Resistance4Authors: Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET03.06 Drug Resistance 1: Antibodies and ADCsLocation: Poster Section 12Poster Board Number: 18Abstract Presentation Number: 2972Tuesday, April 21, 2026 (9:00 AM - 12:00 PM)Title: Glycan-based site specific ADC Achieves Sustained Tumor Control through Improved Payload Delivery and Immune Activation9Authors: Liu Chih-Chun, Tsai Yi-Chien, Huang Jing-Rong, Lo Fei-Yun, Pei Yu, Hsu Ren-Yu, Tu Tzu-Hsuan, Chen Ya-Chi. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.IM02.04 - Adaptive Immunity in CancerLocation: Poster Section 6Poster Board Number: 2Abstract Presentation Number: 4234Title: Advancing ADC therapeutics with next-generation site-specific glycan conjugation and dual-payload flexibility10Authors: Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen,Teng-Yi Huang. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.ET02.03 - Antibody-Drug Conjugates and Linker Engineering 3Location: Poster Section 12Poster Board Number: 1Abstract Presentation Number: 4423The e-posters will be available for browsing at the AACR virtual meeting platform beginning at 12:00 PM PT on April 17, as well as on the OBI Pharma website (www.obipharma.com) beginning on April 18.1 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/45832 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/53853 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/45884 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/50305 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/40516 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/54007 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/54018 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/64749 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/131110 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/5403About OBI PharmaOBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing innovative cancer therapeutics to provide new treatment options for patients with urgent medical needs.OBI's research efforts center on novel antibody-drug conjugates (ADC). Through its patented next-generation conjugation technology platform, Obrion™, OBI has established diverse ADC design modalities. The platform integrates proprietary conjugation and linker technologies, including GlycOBI®, GlycOBI DUO®, EndoSymeOBI®, HYPrOBI®, and the novel irreversible cysteine-conjugation technology ThiOBI® , to advance next-generation ADC solutions. OBI has developed a next-generation suite of ADC programs. These include monospecific ADCs such as OBI-902 (TROP2), which is under Ph1 clinical evaluation, and OBI-904 (Nectin-4); a bispecific single-payload ADC, OBI-201 (HER2 x TROP2); and a bispecific dual-payload ADC, OBI-221 (cMET x HER3). To broaden the applicability of the HYPrOBI® linker technology, OBI has further developed the ThiOBI® technology to enable irreversible cysteine-based conjugation. In addition to its ADC programs, OBI's assets include OBI-3424, a first-in-class AKR1C3-targeted small-molecule prodrug that selectively releases a potent DNA-alkylating agent in the presence of the aldo-keto reductase 1C3 enzyme, which is highly expressed in certain tumors. Additional information can be found at www.obipharma.com.About OBI-902 and OBI-992OBI-902 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells with a drug-antibody ratio (DAR) of 4. TROP2 is highly expressed in a variety of solid tumors such as breast, lung, biliary, bile duct (cholangiocarcinoma), ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.OBI-902 is a novel site-specific glycan-conjugated ADC using OBI's proprietary GlycOBI® platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy across multiple tumors, including NSCLC, triple-negative breast cancer (TNBC), and gastric cancer, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. The IND of OBI-902 was cleared by the United States Food and Drug Administration (US FDA) on April 30, 2025, received Orphan Drug Designation (ODD) from the US FDA for cholangiocarcinoma on Nov. 16, 2025, and gastric cancer (GC), including gastroesophageal junction cancer (GEJC) on December 5, 2025.The Phase 1/2 Study (NCT07124117) is ongoing, with completion of the Phase 1a portion targeted for 1H 2027.OBI-992 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload with drug-to-antibody ratio of 4 (DAR 4) via a cysteine conjugated, hydrophilic and enzyme-cleavable linker. OBI-992 remains stable in circulation and delivers this cytotoxic payload to TROP2-expressing tumor cells, leading to tumor cell death while avoiding off-target toxicities.The US FDA cleared the IND application for OBI-992 in Jan 2024 and subsequently granted Orphan Drug Designation for the treatment of gastric cancer, including GEJC in Aug 2024. The Phase 1/2 Study (NCT06480240) has reached the putative Recommended Phase 2 Dose (pRP2D) and Phase I completion is targeted for 1H 2027.Since December 2021, OBI has been granted by Biosion, Inc. (www.biosion.com) an exclusive license to a TROP2 targeting antibody amino acid sequence in all jurisdictions except Mainland China, Hong Kong and Macau. Biosion holds exclusive rights to that antibody sequence in Mainland China, Hong Kong and Macau. OBI holds commercial rights to OBI-992 and OBI-902 in all jurisdictions except Mainland China, Hong Kong and Macau, while Biosion holds commercial rights to OBI-992 and OBI-902 in Mainland China, Hong Kong and Macau.About OBI-904OBI-904 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody specifically targeting Nectin-4 (Nectin cell adhesion molecule 4), linked to a potent topoisomerase I inhibitor payload with Drug-to-Antibody Ratio of 8 (DAR8) through OBI's proprietary GlycOBI® ADC enabling technologies, powered by a dual-function enzyme, EndoSymeOBI®, and a novel linker, HYPrOBI®. It is a potentially first-in-class and best-in-class glycan-based ADC designed to target multiple cancer types that express Nectin-4. Antitumor activity has been shown across several animal disease models, including HNSCC, CRC, TNBC, cervical and sarcoma cancers; OBI-904 has demonstrated a favorable safety profile in a repeat dose toxicity study in monkeys, and is now in the pre-IND stage of development.About OBI-201OBI-201 is a TROP2 x HER2 bispecific ADC generated by OBI GlycOBI® ADC enabling technologies conjugated with a topoisomerase I inhibitor. Notably, OBI is the first to demonstrate that HER2 and TROP2 can interact and form a protein complex on the cell surface-a groundbreaking discovery facilitated through collaboration with a specialized AI drug discovery partner. OBI-201 offers several advantages over mono-specific TROP2 or HER2 ADCs. By targeting both antigens, it broadens tumor coverage, especially in cancers with heterogeneous or low expression of either target. Dual targeting can enhance tumor selectivity, binding avidity, and internalization, improving payload delivery to cancer cells while potentially reducing toxicity to normal cells. OBI-201 may overcome resistance associated with downregulation of targets after treatment by certain monospecific ADCs.Animal studies revealed that OBI-201 demonstrated significantly superior anti-tumor activity compared to single-target ADCs in drug-resistant breast cancer models with extremely low HER2 expression. OBI-201 was able to sustain tumor growth suppression, indicating its potential to overcome multiple drug-resistance mechanisms. OBI-201 is a next-generation bispecific ADC poised to break through the limitations of single-target ADCs, potentially offering patients a more comprehensive and durable treatment option.About OBI-221OBI-221 is a Bispecific-Dual Payload ADC (BsDpADC), generated by OBI GlycOBI DUO® technologies, targeting cMET and HER3, conjugated with dual payload of MMAE and topoisomerase I inhibitor.In clinical practice, EGFR-targeted therapies have become a key strategy for treating non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) patients. However, tumors often rapidly develop resistance by upregulating cMET and HER3 that, in turn, sustain tumor growth. Moreover, high expressions of cMET and HER3 have been observed in gastric cancer, head and neck cancer, and various other solid tumors, further underscoring the unmet medical needs.To address this challenge, OBI Pharma leverages its proprietary GlycOBI DUO® platform and HYPrOBI® linker to develop a novel bispecific dual-payload antibody-drug conjugate (BsDpADC)-OBI-221. This therapeutic agent simultaneously targets cMET and HER3 while delivering synergistic cytotoxic agents, effectively combating tumor resistance and heterogeneity. This breakthrough design not only addresses an unmet medical need but also represents a forward-looking strategy for next-generation ADC development.OBI-221 holds meaningful potential to overcome resistance to existing EGFR-targeted therapies, potentially offering patients more targeted treatment options while delivering substantial clinical value.About GlycOBI®OBI has developed a unique glycan-based, site-specific ADC technology (GlycOBI®), designed in a Plug and Play format that is compatible with any antibodies, linkers, and payloads, and supports various drug-antibody ratios (DAR)(up to 16). Powered by OBI's proprietary dual-function enzymatic technology EndoSymeOBI® and its hydrophilic linker technology HYPrOBI®, GlycOBI®, a core component of OBI's Obrion™ ADC technology family, enables the generation of site-specific and homogeneous ADCs through an efficient, scalable and streamlined two-step, one-pot conjugation process under GMP conditions.During the conjugation process, GlycOBI® avoids disrupting the antibody structure and ensures that the resulting ADC retains biophysical characteristics comparable to the native antibody. In addition, OBI's linker technology improves payload conjugation efficiency and reduces the propensity for aggregation or degradation, further supporting a stable and well-controlled ADC manufacturing process. GlycOBI® has overcome limitations commonly associated with traditional ADC approaches and has demonstrated improved antitumor activity and stability in various in vivo studies. Notably, the platform supports the conjugation of both cytotoxic small-molecule inhibitors and highly hydrophobic degraders, expanding its applicability to next-generation modalities such as DACs.About GlycOBI DUO®GlycOBI DUO® is a next-generation dual-payload antibody-drug conjugate (ADC) technology built on the GlycOBI® site-specific conjugation platform and its proprietary enzymatic conjugation strategy. It enables the precise and programmable attachment of two distinct payloads to a single antibody with tunable ratios and supports high DAR ratios, including up to DAR24. By combining complementary mechanisms of action, GlycOBI DUO® is designed to enhance antitumor efficacy, address tumor heterogeneity, and improve the overall therapeutic index, with the potential to overcome resistance mechanisms associated with conventional ADCs-representing a promising advancement in next-generation ADC development.About ThiOBI®OBI has developed a novel irreversible, cysteine conjugation ADC platform (ThiOBI®) with improved stability, which can apply to any antibodies, linkers, and payloads. OBI's proprietary ThiOBI® platform including linker technologies (HYPrOBI®) can generate ADCs in different biomolecular formats, including antibody fragments, nanobodies, peptides, and proteins. Furthermore, OBI's HYPrOBI® linker technology has improved conjugation efficiency of the payload and reduced aggregation propensity and also expanded the half-life of the ADC products. ThiOBI has overcome the limitations of traditional cysteine ADCs and achieved better antitumor activity and stability in various in vivo tests.GlycOBI®, EndoSymeOBI®, ThiOBI®, HYPrOBI®, and GlycOBI DUO® are registered trademarks of OBI. Obrion™ is a trademark under registration.Forward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.COMPANY CONTACT:Jukka MuhonenExecutive Director, Business DevelopmentOBI Pharma USA, Inc.1.617.821.0292jukkamuhonen@obipharma.comSOURCE: OBI Pharma USA, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月15日 - (亞太商訊 via SeaPRwire.com) - 品創控股有限公司（「品創控股」或「公司」，連同其附屬公司統稱為「集團」；股份代號：8066）欣然宣佈，集團全資附屬公司賽博幻境（香港）有限公司（「賽博幻境」）於今日隆重舉行《語音 AI 之 Echo 生態戰略全球啟幕盛典》，正式啟動其全球語音 AI 回聲生態系統（Echo Ecosystem，「回聲生態」）戰略，構建從語音數據採集、處理到商業應用的全鏈路閉環。此舉標誌著集團在人工智能語音數據服務領域的戰略佈局邁入全新階段，為集團深化 AI 業務轉型、打造長效增長曲線奠定堅實基礎。針對語音數據採集規模、質量與多樣性的行業困境，賽博幻境創造性推出區塊鏈遊戲與語音數據採集相結合的全新模式。用戶參與遊戲時，完成指定文本的語音錄製任務，既可享受遊戲樂趣，亦可獲得代幣激勵。該「遊戲化採集」模式，可大規模、高效率獲取覆蓋不同年齡、地域、口音與情感表達的真人語音數據，為構建多元化聲音數據庫提供穩定持續的來源。採集完成後，回聲平台透過專業清洗、標註與分類處理，將原始語音轉化為可直接用於 AI 訓練的結構化聲音數據庫。相關數據庫於 AI 數據市場以回聲代幣交易，供全球開發者及企業採購使用，形成「用戶參與採集 — 獲取代幣激勵 — 數據加工處理 — 市場交易流通 — 產業應用賦能」的完整價值鏈閉環。該模式不僅大幅降低語音 AI 開發門檻，更讓數據貢獻者、開發者及終端用戶共享語音 AI 發展所帶來的裨益。「語音 AI 不僅是技術，更是未來數字世界的入口。」賽博幻境首席執行官郭曉鵬先生在盛典上表示，「回聲生態致力於構建語音 AI 時代的基礎設施，透過去中心化的數據採集網絡和開放的聲音數據庫市場，我們將為全球 AI 開發者提供最豐富、最優質的聲音數據資源，推動語音 AI 技術在各行各業的快速落地和應用創新。」當前，人工智能技術加速滲透各行各業，人機對話已成為 AI 應用場景的核心交互方式。語音 AI 技術作為 AI 智能體不可或缺的組成部分，正成為連接人類與數字世界的入口。高品質、多元化的聲音數據庫是 AI 智能體強化訓練的核心基礎，語音 AI 技術發展已進入「數據驅動」新階段，優質聲音數據庫不僅可顯著提升語音合成的情感表現力、語音識別的場景適應性與對話系統的個性化能力，更成為語音 AI 產業發展的核心競爭力與先發優勢所在。品創控股銳意推動業務多元化佈局，把握數字經濟與人工智能產業的蓬勃商機，並憑藉前瞻性轉型，成功構建「私域電商營運 + AI 技術服務」雙輪驅動的業務架構。本次回聲生態全球啟動，是集團深化 AI 業務佈局、推動主營業務向 AI 數據服務轉型的關鍵里程碑。展望未來，集團將以賽博幻境為核心載體，持續深耕語音 AI 技術研發，拓展生態合作網絡，推動技術在智能客服、數字人、元宇宙、智能汽車等前沿領域深度融合；同時深化兩大業務協同效應，強化核心競爭力，推動業務高質量發展，把握全球 AI 產業廣闊機遇，致力為股東創造可持續長期回報。圖片說明 賽博幻境首席執行官郭曉鵬先生講解去中心化語音網絡的價值實現，彰顯品創控股推動語音 AI 技術在各行各業的快速落地和應用創新的決心。關於品創控股有限公司品創控股有限公司的使命是妥善運用公司所獲得的資本與獨特投資機會，為股東提供穩定的優渥收入與獲利。品創控股由六個主要事業部門組成，包括智能卡製造服務、電子商務、人工智能、投資服務、資源回收投資與媒體與娛樂投資，主要業務為生產及銷售智能卡、提供定製智能卡應用系統、私域電子商務平台營運、人工智能語音技術數據服務、提供財務及管理諮詢服務、廢舊金屬銷售及貿易、以及媒體與娛樂行業之投資。公司的總部位於香港，旗下控股公司與投資則遍佈大中華地區。關於賽博幻境（香港）有限公司賽博幻境（香港）有限公司是品創控股有限公司的全資子公司，專注於語音人工智能技術的研發與應用。賽博幻境致力於通過創新的生態模式，打造從數據采集、處理到商業落地的全鏈條語音AI解決方案，助力全球智能語音產業的發展。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - As artificial intelligence adoption accelerates across Southeast Asia, enterprises across the ASEAN region are increasingly establishing structured AI engineering practices to move from experimentation to production-scale deployment.According to Joseph Bosco, Partner Manager, APJ - Prof Services at Databricks, organisations across ASEAN are recognising that sustainable AI adoption depends not only on advanced models but also on robust engineering foundations that ensure reliability, governance and operational scalability.“The early phase of AI adoption focused heavily on experimentation and proofs of concept,” Bosco said. “Across Southeast Asia we are now seeing a shift towards AI engineering practices that prioritise data quality, governance and production readiness.”Markets such as Singapore, Indonesia, Vietnam, Malaysia and Thailand are witnessing strong momentum in enterprise AI adoption as organisations modernise their data infrastructure and invest in advanced analytics capabilities.Industry experts note that AI engineering is becoming a critical discipline that connects AI innovation with enterprise operations. This includes building scalable data pipelines, managing machine learning lifecycle processes and integrating AI systems into business workflows.“Building a model is only one part of the challenge,” Bosco said. “The real work lies in creating reliable data pipelines, managing model lifecycle and embedding AI into operational systems.”Across ASEAN, many enterprises continue to manage complex data environments spanning legacy systems, multiple cloud platforms and software-as-a-service applications. Consolidating these fragmented data sources into unified platforms is increasingly seen as a prerequisite for scaling AI initiatives.Technology partners and consulting firms across the region are responding by developing dedicated AI engineering practices that combine expertise in data engineering, machine learning, generative AI and governance frameworks.These capabilities are already being applied across key sectors including financial services, telecommunications, and manufacturing.Bosco noted that Southeast Asia’s rapidly expanding data economies are creating a particularly dynamic environment for AI engineering talent and innovation.“As organisations across ASEAN continue to invest in data transformation, AI engineering will become an essential capability that enables enterprises to operationalise AI safely and effectively,” he said. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月15日 - (亞太商訊 via SeaPRwire.com) - 中國領先循環經濟產業新消費公司轉轉集團（下稱：轉轉）近日宣布，其自主研發的AI鑒定產品「AI拍圖驗真」在二手奢侈品鑒定領域取得重大突破，鑒定準確率實現了LV包袋鑒定錯誤率不足萬分之一、GUCCI包袋零錯誤的卓越表現；鑒定效率提升近900倍至「1秒出結果」。集團今年將逐步把AI鑒定拓展至CHANEL、Hermès等熱門品牌，並於未來延伸至腕表等其他二手品類，構建全品類AI鑒定矩陣。憑藉其頂尖AI鑒定能力及創新業務模式的領先優勢，轉轉同步計劃在香港設立國際業務總部，正式開啟全球化佈局。 作為中國頂尖二手交易平台，轉轉自2015年成立以來發展迅速，旗下擁有轉轉、找靚機、紅布林等多個知名二手消費品牌。當前中國二手閑置賽道備受資本與市場矚目，轉轉亦憑藉首創的二手質檢「官方驗」服務脫穎而出。集團已獲包括騰訊、小米、58集團在內的多家知名企業或投資者支持，上一輪融資估值達逾30億美元（約234億港元），去年營收總額突破200億元人民幣，擁有超過4億註冊用戶、5,000萬月活躍用戶。 （圖為北京「超級轉轉」二奢倉店）有別於以Carousell、閑魚等企業為代表的傳統C2C模式，轉轉透過成熟的C2B2C商業模式，以「平台居中、專業鑒定、品質保證」提供差異化平台服務。其首創的「官方驗」服務在對回收商品全方位嚴格檢測後，為其提供一份專屬的質檢報告並公開展示，絕大部分官方驗商品，都可享有7天無理由退貨、一年平台質保、內陸包郵等增值服務。轉轉透過標準化質檢與售後保障，例如履行「驗了再發貨」、「不滿意可退」、「驗錯了就賠」等策略，為消費者提供「所見即所得」的優質體驗。 （圖為轉轉青島智慧質檢中心）技術驅動是轉轉穩居行業領先地位的核心引擎。轉轉去年特別成立了AI事業部，三年內擬投入20億元人民幣研發AI質檢、智能匹配等工具。今年初上線的「AI拍圖驗真」，深度應用於二手奢侈品鑒定領域，系統基於海量真實商品圖片資料庫與深度學習演算法，將傳統需時15分鐘的人工鑒定大幅壓縮至「秒級鑒定」，最快1秒即可出結果，效率提升近900倍；同時在核心包袋品類的鑒定上，更創下錯誤率不足萬分之一的超高準確率（上線至今，LV包袋累計鑒定逾萬單以上，僅錯一單，錯誤率不足萬分之一；GUCCI包袋累計鑒定近3000單，實現零錯誤），徹底打破了傳統非標品交易及人工鑒定中的標準不一、效率樽頸等難題。 轉轉集團創辦人兼行政總裁黃煒表示：「轉轉集團在過去十年間通過持續的技術創新和戰略整合，確立了在中國二手交易市場的領導地位，我們深信領先的技術與質檢能力是打破二手交易壁壘的關鍵。轉轉致力引領中國的二手消費模式，不斷刷新消費者的二手消費體驗，我們對即將在香港設立國際業務總部感到振奮，亦是標誌著轉轉從中國市場邁向國際舞台的重要里程碑。」 （圖為轉轉APP內商品AI鑑定資訊）關於轉轉轉轉集團成立於2015年，是中國領先的循環經濟產業新消費公司，旗下擁有轉轉、找靚機、采貨俠、俠客匯、紅布林等多個二手電商品牌，業務覆蓋手機3C、奢侈品、圖書、潮玩等百餘種餘種品類二手商品交易，在全國佈局超過1,100多家線下門店和超過3,000人的上門回收團隊，通過人工智能質檢技術和創新的C2B2C商業模式，致力解決非標品交易的信任難題，為消費者帶來有「質價比」的二手好物。轉轉作為全國有履約二手商品交易平台的領導企業，去年已錄得超過4億註冊用戶、5000萬月活躍用戶。「技術驅動＋平台服務」為核心引擎，轉轉特設AI事業部，在國立首創二手質檢「官方驗」服務，並先後自主研發AI估價系統、AI拍圖驗真等核心技術產品，打造了二奢行業的頂尖AI鑒定能力，為全球知名熱門的奢侈品牌包袋品類提供秒級且精準的真偽鑒定，持續引領中國二手交易市場向標準化、數字化邁進。傳媒垂詢，請聯絡：轉轉集團公關部 Alan Wei：weixi@zhuanzhuan.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

KUALA LUMPUR, Malaysia, April 14, 2026 — Exito Media Concepts today announced the 46th Edition of the Digital Transformation Summit Malaysia 2026, convening on 23rd April 2026 at the Hyatt Regency Kuala Lumpur Midtown. The summit will bring together more than 200 C-Level executives, technology directors, and government leaders to address the strategic and operational imperatives shaping Malaysia's next phase of digital growth.Now in its 46th edition and part of a series spanning 11+ countries, the summit has established itself as one of Asia Pacific's most consequential forums for enterprise technology leadership.The Strategic Context: Malaysia's Digital Economy at a Critical JunctureMalaysia's digital economy is undergoing a structural shift. Driven by targeted government-led initiatives and accelerating enterprise adoption of artificial intelligence, the Internet of Things, and Web 3.0, organizations across every sector are fundamentally reimagining how they operate, compete, and deliver value.The opportunity is significant. Yet the path to enterprise-wide transformation demands more than technology investment — it requires navigating complex cybersecurity environments, integrating legacy infrastructure with modern digital architecture, developing organizational capabilities at pace, and embedding a culture of innovation that sustains long-term resilience. For Malaysia's business leadership, strategic clarity has never been more consequential.The Digital Transformation Summit Malaysia 2026 is designed precisely for this inflection point.Enterprise Transformation in PracticeThe business case for bold digital action is already being written across Malaysia. A leading domestic enterprise recently undertook a comprehensive digital transformation initiative — transitioning to a cloud-first infrastructure supported by advanced data analytics and AI capabilities.The results were measurable and material: automating key operational processes delivered significant gains in efficiency and organizational agility. The concurrent deployment of robust cybersecurity frameworks ensured data integrity and regulatory compliance. Simultaneously, structured workforce upskilling programmes enabled teams to perform with confidence in an evolving technology environment.The outcome: improved business performance, deeper customer engagement, and a materially stronger competitive position within Malaysia's digital economy. It is precisely this calibre of real-world insight that the Summit is built to surface and scale.Event OverviewThe 46th Edition of the Digital Transformation Summit Malaysia 2026 is part of a globally recognized series of events hosted across 11+ countries. This edition will convene more than 200 C-Level Executives, Directors, Heads of Technology, Government leaders, and digital transformation leaders from across industries.Through expert-led keynotes, panel discussions, and real-world case studies, the summit will highlight innovative strategies, emerging technologies, and actionable insights that empower organizations to drive digital growth and operational excellence.Date: 23rd April 2026Time: 09:00 AM to 05:00 PMVenue: Hyatt Regency Kuala Lumpur MidtownWebsite: https://digitransformationsummit.com/malaysia/Summit Agenda: Technology Priorities Shaping 2026Delivered through expert-led keynotes, high-impact panel discussions, and documented case studies, the Summit agenda will address the technology priorities most consequential to enterprise leaders this year:Artificial Intelligence & Machine Learning Embedding intelligent decision-making and automation across core business functions — from supply chain to customer experience to financial operations.Web 3.0 & Emerging Technologies Navigating decentralized innovation and unlocking new digital ecosystems with long-term enterprise relevance.Internet of Things (IoT) Advancing operational connectivity and efficiency across industries through integrated sensor and data infrastructure.Quantum Computing Examining the practical and strategic implications of the next frontier in computational capability.Cybersecurity & Data Protection Strengthening enterprise digital resilience against an increasingly sophisticated and expansive threat landscape.Cloud & Scalable Infrastructure Building the foundational agility, continuity, and scalability demanded by modern enterprise growth.Digital Culture & Transformation Strategy Developing the leadership frameworks and organizational behaviours that sustain transformation well beyond initial implementation.Data-Driven Decision Making Harnessing analytics to convert raw data into competitive intelligence and measurable business outcomes.About Exito Media ConceptsExito — the word for success — is both the name and the operating philosophy of one of the world's most active B2B events and media organizations. Over 16 years, Exito has built a reputation for delivering 240+ conferences annually across technology, digital transformation, cybersecurity, healthcare, and emerging enterprise sectors worldwide.Every Exito event is defined by meticulous agenda curation, access to world-class speaker communities, and a commitment to market-driven insight that translates directly into strategic value for attendees, sponsors, and partners. The result is a global platform trusted by thousands of senior executives to inform their most consequential decisions.Media ContactPrakruthi NayakaMedia and PR Executive, Exito Media ConceptsEmail: prakruthi.nayaka@exito-e.comWebsite: https://digitransformationsummit.com/malaysia/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月15日 - (亞太商訊 via SeaPRwire.com) - 4月13-14日，2026年世界互聯網大會亞太峰會在香港會議展覽中心舉辦。百望股份首席戰略官劉揚發表了題為《全球稅務合規：從"財稅數字化"到"中國企業商業信用基礎設施"》的主題演講，深度分享百望股份全球化戰略布局與落地進程，全面展示了百望以AI Agent重構跨境稅務合規體系、搭建中國企業商業信用基礎設施的創新實踐。本次峰會以"數智賦能 創新發展——攜手構建網絡空間命運共同體"為主題，由世界互聯網大會主辦，香港特別行政區政府承辦，香港特別行政區政府創新科技及工業局等協辦。香港特別行政區行政長官李家超出席開幕式並致辭。來自全球50餘個國家和地區的政府部門部長級官員、國際組織高級別代表、駐華使節、互聯網領軍企業代表，以及專家學者等約千名嘉賓參會。百望以商業信用模型架構為核心，築造AI能力壁壘本次世界互聯網大會的亮相，是百望股份上市以來完成AI戰略轉型後，首次在世界級行業論壇的重磅發聲，也是企業全球化戰略的一次全面公開發布。會上，百望股份宣告已完成全球化智能科技公司的全面能力准備，以商業信用模型為核心架構，正式開啟全球化發展新篇章。百望股份是本次大會中唯一一家實現垂直大模型企業級應用落地、且擁有規模化真實商業案例的企業，充分印證了在AI企業級應用賽道的領先身位，全面彰顯了百望股份核心戰略的前瞻性與正確性，驗證了以數據智能為核心、以AI Agent為抓手、以全球化布局為增長曲線的長期戰略布局的精准判斷。基於對AI Agent 時代企業級需求的深度理解，百望股份以動態商業信用模型為核心，完成了產品架構的全面升級，打造了"底層底座-能力中樞-智能執行"的完整閉環產品體系。 百望股份之能成為中國企業商業信用基礎設施的構建者，核心根基就藏在這一架構的底層設計邏輯之中。整個架構以算力平臺為底層支撐，向上搭建了數據中臺、AI中臺、能力中臺三位一體的技術中臺體系。基於交易關系、商品關系、制度關系、金融關系、雇傭關系五大維度，百望股份形成了以百望企信碼為底層底座，以百鏈、百信、百策為數據核心能力中樞，以百望百寶、百望百搭為智能執行應用的群體智能矩陣。區別於傳統財稅軟件的功能疊加模式，百望股份打造的是可生長、可擴展的智能技術底座，這也是商業信用基礎設施能夠持續迭代、適配全球多元場景的核心前提。作為一家善用數據的科技公司，百望股份始終將真實交易數據作為AI時代的核心競爭力，過去十年累計處理發票超 260 億張，沉澱了覆蓋 9600萬餘個市場主體的海量高質量真實交易底賬數據，成為企業AI 能力建設的核心燃料！百望Tax-Swift護航中企全球化征程，全面印證場景落地能力作為百望股份全球化戰略的核心場景落地產品，Tax-Swift全球虛擬稅務平臺基於沉澱10年的監管科技與規則引擎能力，完成了全球化適配與升級，為中國企業的全球化征程搭建起全鏈路的合規屏障。具體而言，Tax-Swift以AI技術為核心驅動力，構建了覆蓋全球稅務合規全流程的閉環服務體系。平臺依托全球引擎基座、發票引擎、稅務規則引擎、國家適配器四層核心架構，可自動完成多語言轉換、實時匯率校准、多格式報文轉換、電子簽名校驗、智能算稅算法、合規風險過濾、稅收優惠適配等全流程操作，實現了企業ERP系統到全球各國稅務系統的無縫直連，可深度適配全球主流稅務監管體系。目前，平臺已覆蓋10餘種主流語言、200餘種票據格式標准、3萬餘條國際財稅規則，已在多個中企出海場景落地見效。例如，某中國餐飲集團出海越南時，接入Tax-Swift平臺後，順利完成了越南當地門店的稅務合規體系搭建，實現了規模化落地。今年初，百望再度升級推出Tax-Swift Bai-Claw（全球稅務數字員工平臺），可覆蓋全球50餘個國家和地區的財稅合規需求，AI數字員工全面掌握權威財稅政策、行業知識與專業技能，可根據企業需求定制化部署，成為中企出海隨身隨行的合規哨兵。百望股份CSO劉揚在演講中表示："政策、數據、AI與全球化正在形成新的共振。交易無國界，納稅有主權，全球數字貿易正在進入主權卡位與信用卡位的全新階段。百望股份期望以本次峰會為契機，持續深化技術創新與產業實踐，以數智能力築牢中國企業出海的合規屏障，以商業信用基礎設施賦能全球貿易的高質量發展，攜手各界夥伴共同賦能國家一帶一路戰略，為構建網絡空間命運共同體貢獻力量。"隨著AI技術的持續深化與全球化布局的穩步推進，百望股份正在以技術創新打破跨境貿易的合規壁壘，為中國企業出海鋪就一條安全、高效的數字化通路，在全球數字貿易的新賽道上，書寫中國科技企業的全新篇章。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - April 14, 2026) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to announce that it has filed the independent National Instrument 43-101 Technical Report entitled "Preliminary Economic Assessment of the Hat Polymetallic Project, British Columbia, Canada" (the "Technical Report") on SEDAR+ at www.sedarplus.ca and it can also be viewed on the Company's website at www.doubleview.ca. The Technical Report supports the positive Preliminary Economic Assessment ("PEA") results for the Company's 100%-owned Hat polymetallic porphyry project ("Hat" or the "Project"), located in northwestern British Columbia, as announced on March 2, 2026 and clarified on March 23, 2026.The PEA demonstrates robust project economics for the Hat Project, including:NPV:After-tax NPV(5%) of C$6.73 billion and IRR of 23% at Consensus Metal PricesAfter-tax NPV(5%) of C$13.53 billion and IRR of 39% at Spot Metal PricesNPV Including scandium and the associated processing circuit:After-tax NPV(5%) of C$7.27 billion and IRR of 19% at Consensus Metal PricesAfter-tax NPV(5%) of C$14.85 billion and IRR of 32% at Spot Metal PricesThree processing scenarios were evaluated-Scenario A1 (A1) a Cu-Au-Ag-Co flotation base case using current testwork recoveries1, Scenario A2 (A2), the same base case using expected recoveries1, and Scenario B (B), a Cu-Au-Ag-Co flowsheet with an added hydrometallurgical circuit and scandium recovery circuit, with results indicating the Project is financially attractive even without the scandium component.Highlights:Robust Project Economics: The PEA demonstrates a high-margin operation with an After-Tax NPV(5%) of C$4.96 billion (A1), C$6.73 billion (A2), or C$7.27 billion (B), and an IRR of 19% (A1), 23% (A2), or 19% (B) at analyst consensus metal prices2. Using a spot-price scenario3, the Project delivers a compelling after-tax NPV(5%) of C$11.05 billion (A1), C13.53 billion (A2), or C$14.85 billion (B) and an IRR of 34% (A1), 39% (A2), or 32% (B).Sensitivity Highlight: Project economics show the greatest leverage to overall metal prices, with NPV (5%) ranging from C$3.2 billion to C$10.2 billion (IRR: 14%-32%) at ±20% on all metals; even under additional +20% CAPEX and +20% OPEX sensitivities, applied on top of a 25% contingency already embedded in the base case, all scenarios deliver IRRs of 16% or better, and Scenario B provides additional scandium oxide upside with NPV(5%) of C$6.5 billion-C$8.1 billion (IRR: 18%-20%) at ±40% metal price.Scale and Longevity: The mine plan supports a multi-decade life of 25 years at a 120,000 tonnes-per-day processing rate, underpinned by a resource base of 609 Mt at 0.43% CuEq4 in the Measured and Indicated categories and 503 Mt at 0.41% CuEq4 in the Inferred category.High-Output Production Profile B: Envisioned as a conventional large-scale open-pit operation, the Project is expected to produce an average of over 74 kt of copper, 254 koz of gold, 376 koz of silver and 2.7 kt of cobalt annually during the first 10 years, with life-of-mine (LOM) average production of 67.6 kt Cu, 217 koz Au, 348 koz Ag, 2.5 kt Co, and 128 tonnes of scandium oxide per year. (NOTE: based on publicly reported 2024 North American cobalt mine production of approximately 3,800-4,000 tonnes (Natural Resources Canada; U.S. Geological Survey), the projected cobalt output is estimated to represent approximately 69% of current regional mined supply).Strategic Importance for Critical Minerals: The Project is positioned as a primary North American source of copper, scandium, and cobalt. With approximately 2.42 billion pounds of copper, 80 million pounds of cobalt and 2,415 tonnes of scandium oxide contained5 in the Measured and Indicated categories, the Project represents an important discovery of critical minerals.Stable, Supportive Jurisdiction: Located in a premier mining district in British Columbia, the Project benefits from a stable regulatory environment. The Company is committed to engaging with local First Nations in a respectful manner and to working toward positive and constructive relationships as the Project advances.Catalyst for Development: The PEA serves as the technical foundation for an immediate transition into a Pre-Feasibility Study (PFS), providing a clear roadmap for early works and permitting activities in 2026 and 2027.Farshad Shirvani, President and CEO of Doubleview Gold Corp., commented: "The filing of the full PEA Technical Report solidifies the robust economics outlined in March. With an after-tax NPV(5%) reaching up to C$7.27 billion at consensus prices and up to C$14.85 billion at spot prices, we believe the Hat Project is emerging as a Tier 1 asset. It is a large-scale, long-life polymetallic opportunity in a premier jurisdiction with strong exposure to critical metals including copper, scandium and cobalt. We look forward to advancing this strategic asset toward pre-feasibility while continuing to unlock value from its copper, gold, scandium and cobalt potential."The Company cautions that the PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. There is no certainty that the PEA will be realized. Mineral resources that are not mineral reserves do not have demonstrated economic viability.Qualified PersonsThe Technical Report was prepared in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects. The scientific and technical information contained in this news release has been reviewed and approved by the following Qualified Persons, each responsible for their respective areas of the Technical Report:Tomasz Wawruch - Geology and Mineral Resource EstimateShervin Teymouri - Mining engineering, capital and operating cost estimates, financial analysisAndrew Carter - Metallurgical testwork, recovery assumptions, and process metallurgyAndre de Ruijter - Process design, plant engineering, and process capital and operating costsFranky Li - Tailings management and tailings storage facility designJayesh Rami - Site infrastructure, civil works, access roads, and supporting facilitiesDoubleview acknowledges that the Project is located on the traditional territories of the Tahltan Nation and the Taku River Tlingit First Nation, and recognizes their enduring relationship to and stewardship of the land and waters. Doubleview is committed to respectful, transparent, and ongoing engagement with First Nations and local communities whose territories overlap the Project area and access routes, with a focus on protecting water and the environment and advancing responsible development.Readers are encouraged to review the full Technical Report on the Company's website at www.doubleview.ca and on SEDAR+ at www.sedarplus.ca for complete details, assumptions, risks, sensitivities, and qualifications.About Doubleview Gold Corp.Doubleview Gold Corp., a mineral resource exploration and development company based in Vancouver, British Columbia, Canada, is publicly traded on the TSX Venture Exchange (TSXV: DBG), the OTCQB (DBLVF), the Berlin Stock Exchange (GER: A1W038), and the Frankfurt Stock Exchange (1D4). Doubleview identifies, acquires, and finances precious and base metal exploration projects in North America, particularly in British Columbia. The Company increases shareholder value through the acquisition and exploration of quality gold, copper, cobalt, scandium, and silver properties-collectively critical minerals-and through the application of advanced, state-of-the-art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.On behalf of the Board of Directors,Farshad ShirvaniPresident & CEOOn behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold CorpVancouver, BC Farshad ShirvaniPresident & CEOInstitutional Line: (604) 607-5470T: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292439 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ATLANTA, GA, Apr 14, 2026 - (ACN Newswire via SeaPRwire.com) - OMP, a leader in AI-powered supply chain planning, is bringing Procter & Gamble to the Gartner Supply Chain Symposium/Xpo™ 2026 in Orlando to present its autonomous supply chain transformation. The consumer goods giant will share how it is building capabilities, enhancing data foundations, and redesigning operations around decision quality with OMP's Unison Planning™.The Gartner stage appearance caps a period of significant recognition for the collaboration. OMP was named one of six recipients of P&G's External Business Partner Excellence Award in the Global Business Services and IT category, recognizing innovation, commercial impact, and operational excellence across P&G's network of more than 50,000 global partners.P&G's journey to autonomous, decision-centric planning at scaleDaniela Cima, One Supply Transformation Senior Vice President, and Renato Scaini, Supply Chain Platform Transformation and IT Planning Vice President, will share how P&G is redefining what autonomous, decision-centric planning looks like in practice. This session will explore how P&G's "One Supply Chain Strategy" is building enhanced data foundations, redesigning operations, and embedding decision quality across its supply chain.The goal is an empowered team that spends less time on routine tasks and more time on high-value decision-making, elevating performance across the entire value chain. Attendees will walk away with concrete insights into the structures, culture, and enablers shaping P&G's next era of intelligent planning at scale, with decision velocity at the heart of it all.Sign up for the sessionAstraZeneca leads CSCO Boardroom on autonomous planningOMP is also hosting an exclusive CSCO Boardroom session on Monday, May 4 (4:00-4:45 PM), featuring Arun Krishnan, SVP of Global Supply Chain & Strategy at AstraZeneca, and Philip Vervloesem, Chief Commercial & Markets Officer at OMP. The session explores how AstraZeneca is moving away from periodic cycles toward always-on, decision-centric operations at scale, covering the operating model choices, governance structures, and talent and technology investments that shape that path. Seating is limited and available on request.Request your sessionExplore decision velocity at the OMP boothOMP will be present throughout the Gartner Supply Chain Symposium/Xpo™ (May 5 to 7, Orlando) at booth 322, demonstrating how Unison Planning™ helps organizations move beyond calendar-based planning toward always-on supply chain orchestration. See how integrated planning, enhanced by the latest AI advancements, improves scenario modeling, strengthens collaboration, and drives measurable business results.Join OMP at Gartner to hear P&G's and AstraZeneca's journeys firsthand and discover how to accelerate your path to smarter, faster supply chain decisions. Get in touch.Session at a glanceTitle: "OMP: How P&G is pioneering the next era of autonomous supply chain orchestration"Speakers:Daniela Cima - One Supply Transformation SVP at P&GRenato Scaini - Supply Chain Platform Transformation and IT Planning VP at P&GWhen: Tuesday, May 5, 2026, 11:30 AM - 12:00 PMWhere: Walt Disney World Swan and Dolphin Resort, Orlando, FLTo see where you can meet OMP next, visit their events calendar here.Solution and product inquiriesContact OMP+32 3 650 22 11Media inquiriesKira Perdue (Carabiner)SOURCE: OMP Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PHILADELPHIA, PA, Apr 14, 2026 - (ACN Newswire via SeaPRwire.com) - Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, and AgSensor Solutions, LLC ("AgSensor") today announced the closing of a definitive consulting partnership agreement to identify, value, and tokenize high-value agricultural data assets.The partnership enables Datavault AI to leverage AgSensor's deep domain expertise in the agricultural technology sector to source and vet companies with significant data assets suitable for the Company's patented Information Data Exchange® ("IDE"), DataScore®, and DataValue® blockchain tokenization platforms. The consulting partnership targets key segments including soil sensing, carbon and sustainability data, agricultural IoT platforms, and regenerative agriculture environmental, social, and governance data firms.By integrating AgSensor's specialized industry knowledge with Datavault AI's monetization infrastructure, the companies aim to create a new class of liquid, transparent digital assets derived from the $5 trillion global agricultural economy1. This initiative provides agricultural producers and technology providers with a compliant pathway - consistent with applicable securities, data privacy, and anti-money-laundering regulations - to unlock the latent value of their data while offering investors exposure to critical sustainability and food security metrics.Nathaniel T. Bradley, CEO of Datavault AI, stated: "Our partnership with AgSensor Solutions is a pivotal step in expanding our RWA tokenization strategy into the vital agricultural sector. Data is the new crop for the modern farmer, and by applying our patented valuation and exchange technologies to soil and sustainability metrics, we are creating a transparent marketplace for agricultural intelligence. This consulting partnership ensures that high-value ag-data is properly qualified and positioned for global monetization."Michael J. DeSa, Co-Founder and CEO of AgSensor, added: "Partnering with Datavault AI allows us to bridge the gap between advanced agricultural sensing and the digital economy. There is an immense volume of high-quality data being generated in the field that remains undervalued. Through this agreement, we are providing the industry with the tools to tokenize these assets, driving new revenue streams for regenerative practices and enhancing the overall value of the agricultural data ecosystem."The strategic alignment focuses on sourcing prospects with high-value data assets, refining product positioning for the agricultural market, and facilitating the integration of these assets into Datavault AI's product lines. This transaction further solidifies Datavault AI's leadership in tokenizing diverse real-world assets and establishes a benchmark for the valuation and exchange of strategic agricultural data.1 According to the Food and Agriculture Organization of the United Nations (FAO), the gross value of global primary agricultural production exceeds $5 trillion annually. Source: World Bank/FAO (2024), https://blogs.worldbank.org/en/voices/do-costs-global-food-system-outweigh-its-monetary-valueAbout Datavault AI Inc.Datavault AI™ (NASDAQ:DVLT) is a pioneer in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company's cloud-based platform delivers comprehensive solutions across its Acoustic Sciences and Data Sciences divisions. Datavault AI's Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies for spatial and multichannel wireless, high-definition sound transmission, including intellectual property covering audio timing, synchronization, and multi-channel interference cancellation.The Data Science Division harnesses Web 3.0 and high-performance computing to enable experiential data perception, valuation, and secure monetization. The platform serves multiple industries, including sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more.The IDE enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. Datavault AI's technology suite is fully customizable and includes AI and machine learning automation, third-party integration, detailed analytics, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more at www.datavaultsite.com.About AgSensor SolutionsAgSensor Solutions is a strategic consultancy specializing in the identification and optimization of agricultural technology and data assets. The firm focuses on connecting high-value agricultural data providers with advanced monetization and exchange platforms to drive innovation in soil health, carbon sequestration, and sustainable farming. Learn more at www.agsensorsolutions.com.Forward-Looking Statements: This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. ("Datavault AI," the "Company," "us," "our," or "we") and our industry that involve risks and uncertainties. Such forward-looking statements include, but are not limited to, statements regarding future events, the expected benefits of the consulting partnership with AgSensor, anticipated suitability of the Company's proprietary IDE, DataScore®, and DataValue® platforms to digitize ownership interests in the agriculture sector through blockchain-based tokenization, and expected operational, technical, and commercial outcomes of the Company's commercial strategy, and the projected direction and market impacts of regulatory changes with respect to digital assets.Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: the ability of the Company and AgSensor to identify, value and tokenize agricultural data assets; the performance, timing, or success of the deployment of the Company's proprietary IDE, DataScore®, and DataValue® platforms; changes in market demand for Datavault AI's services and products; changes in economic, market, or regulatory conditions; risks relating to evolving regulatory frameworks applicable to tokenized assets; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC's website at www.sec.gov.The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments it may make.Media Contactmarketing@dvlt.aiInvestor ContactEdward BargerVP, Investor Relationsir@dvlt.aiebarger@dvlt.aiSOURCE: Datavault AI Inc Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

喬治亞州亞特蘭大, 2026年4月14日 - (亞太商訊 via SeaPRwire.com) - 人工智慧驅動的供應鏈規劃領導者 OMP，將攜手寶潔（Procter & Gamble）出席於奧蘭多舉行的 2026 年 Gartner 供應鏈研討會暨博覽會™，展示其自主供應鏈轉型成果。這家消費品巨頭將分享如何透過 OMP 的 Unison Planning™，圍繞決策品質來建立能力、強化數據基礎並重新設計營運。此次在Gartner舞台的亮相，為雙方合作獲得的重大認可畫下句點。OMP獲選為寶潔「外部商業夥伴卓越獎」全球商業服務與IT類別的六家得主之一，此獎項旨在表彰寶潔全球逾50,000家合作夥伴網絡中展現的創新、商業影響力及營運卓越性。寶潔邁向大規模自主、決策導向規劃的歷程「One Supply」轉型資深副總裁丹妮拉·西瑪（Daniela Cima）與供應鏈平台轉型及IT規劃副總裁雷納托·斯卡尼（Renato Scaini）將分享寶潔如何重新定義自主、以決策為中心的規劃在實務中的樣貌。本場次將探討寶潔的「One Supply Chain Strategy」如何建立強化數據基礎、重新設計營運流程，並將決策品質融入整個供應鏈。目標是打造一支賦能團隊，讓成員減少耗費在例行任務上的時間，並將更多精力投入高價值的決策制定，從而提升整個價值鏈的績效。與會者將深入了解塑造寶潔下一代大規模智慧規劃的結構、文化與驅動因素，而決策速度正是這一切的核心。報名參加本場次 https://pr.report/kml0 阿斯特捷利康（AstraZeneca）於 CSCO Boardroom 主講自主規劃OMP 亦將於 5 月 4 日（週一）下午 4:00 至 4:45 舉辦一場 CSCO Boardroom 專場會議，主講嘉賓包括阿斯特捷利康全球供應鏈與策略資深副總裁 Arun Krishnan，以及 OMP 首席商業與市場官 Philip Vervloesem。本場次將探討阿斯特捷利康如何從週期性運作轉向大規模的「持續運作、以決策為核心」模式，涵蓋塑造此轉型路徑的營運模式選擇、治理架構，以及人才與技術投資。席位有限，需提前預約。預約參與 https://pr.report/kml9 親臨 OMP 展位探索決策速度OMP 將於 Gartner 供應鏈研討會暨博覽會™（5 月 5 日至 7 日，奧蘭多）期間在 322 號展位設攤，展示 Unison Planning™ 如何協助企業突破以日曆為基礎的規劃模式，邁向全天候運作的供應鏈協調。親身體驗整合式規劃如何透過最新 AI 技術的加持，提升情境建模能力、強化協作，並驅動可量化的商業成果。歡迎蒞臨 Gartner 會場與 OMP 交流，親耳聆聽 P&G 與 AstraZeneca 的實踐經驗，並探索如何加速邁向更智慧、更快速的供應鏈決策。立即聯繫我們。議程簡介主題：「OMP：P&G 如何開創自主供應鏈協調的下一時代」講者：• Daniela Cima - P&G 統一供應轉型資深副總裁• Renato Scaini - 宝洁公司供应链平台转型与IT规划副总裁时间：2026年5月5日（星期二）上午11:30 - 12:00地点：佛罗里达州奥兰多市华特迪士尼世界天鹅与海豚度假酒店如需了解OMP的下一场活动地点，请点击此处查看活动日历。解决方案与产品咨询联系 OMP+32 3 650 22 11媒体咨询基拉·珀杜（Carabiner）来源：OMP Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

賓夕法尼亞州費城, 2026年4月14日 - (亞太商訊 via SeaPRwire.com) - Datavault AI Inc.（「Datavault AI」或「本公司」） （納斯達克代碼：DVLT），一家專注於數據變現、憑證認證、數位互動及實物資產（「RWA」）代幣化技術的供應商，與 AgSensor Solutions, LLC（「AgSensor」）今日宣布，已正式簽署最終諮詢合作協議，旨在識別、評估及將高價值農業數據資產代幣化。透過此次合作，Datavault AI 將能運用 AgSensor 在農業科技領域的深厚專業知識，發掘並審核擁有大量數據資產且適合本公司專利技術——Information Data Exchange®（「IDE」）、DataScore® 及 DataValue® 區塊鏈代幣化平台——的企業。此諮詢合作夥伴關係鎖定關鍵領域，包括土壤感測、碳與永續發展數據、農業物聯網平台，以及再生農業環境、社會與治理（ESG）數據公司。透過整合 AgSensor 的專業產業知識與 Datavault AI 的變現基礎設施，雙方旨在從規模達 5 兆美元的全球農業經濟體中，創造出一類源自該領域、兼具流動性與透明度的全新數位資產¹。此舉為農業生產者與技術供應商提供了一條符合相關證券、資料隱私及反洗錢法規的合規途徑，使其能釋放資料的潛在價值，同時讓投資者得以接觸至關重要的永續發展與糧食安全指標。Datavault AI 執行長納撒尼爾·T·布拉德利（Nathaniel T. Bradley）表示：「與 AgSensor Solutions 的合作，是我們將實物資產（RWA）代幣化策略拓展至關鍵農業領域的關鍵一步。數據是現代農民的新作物，透過將我們的專利估值與交易技術應用於土壤及永續發展指標，我們正在打造一個透明的農業智慧市場。這項諮詢合作夥伴關係，將確保高價值的農業數據獲得適當認證，並為全球貨幣化做好準備。」AgSensor 共同創辦人暨執行長 Michael J. DeSa 補充道：「與 Datavault AI 合作，讓我們得以彌合先進農業感測技術與數位經濟之間的鴻溝。田間產生了海量的高品質數據，但這些數據至今仍被低估。透過此協議，我們將為業界提供將這些資產代幣化的工具，為再生農業實踐開闢新的收入來源，並提升農業數據生態系統的整體價值。」此次戰略合作聚焦於發掘擁有高價值數據資產的潛在客戶、優化農業市場的產品定位，並促進這些資產整合至 Datavault AI 的產品線中。此項交易進一步鞏固了 Datavault AI 在將多元現實世界資產代幣化方面的領導地位，並為戰略性農業數據的估值與交易樹立了標竿。1 根據聯合國糧食及農業組織（FAO）數據，全球初級農業生產總值每年超過 5 兆美元。來源：世界銀行／FAO（2024）， https://blogs.worldbank.org/en/voices/do-costs-global-food-system-outweigh-its-monetary-value 關於 Datavault AI Inc.Datavault AI™（納斯達克代碼：DVLT）是 Web 3.0 環境中以人工智慧驅動的數據體驗、資產估值及變現領域的先驅。該公司的雲端平台透過其聲學科學與數據科學兩個部門，提供全面的解決方案。Datavault AI 的聲學科學部門擁有 WiSA®、ADIO® 及 Sumerian® 等專利技術，專注於空間與多聲道無線高解析度聲音傳輸，其智慧財產權涵蓋音訊時序、同步化及多聲道干擾消除等領域。資料科學部門運用 Web 3.0 及高效能運算技術，實現體驗式數據感知、估值與安全變現。該平台服務於多個產業，包括體育與娛樂、活動與場館、生物科技、教育、金融科技、房地產、醫療保健、能源等領域。該整合開發環境（IDE）透過將實體世界物件安全地綁定至不可變更的元數據，實現數位孿生以及姓名、形象與肖像的授權，從而促進具備完整性的負責任人工智慧發展。Datavault AI 的技術套件完全可自訂，涵蓋人工智慧與機器學習自動化、第三方整合、詳細分析、行銷自動化及廣告監測。公司總部位於賓夕法尼亞州費城。更多資訊請造訪關於 AgSensor SolutionsAgSensor Solutions 是一家專注於識別與優化農業技術及數據資產的戰略顧問公司。該公司致力於將高價值的農業數據供應商與先進的變現及交易平台相連結，以推動土壤健康、碳封存及永續農業領域的創新。更多資訊請瀏覽 www.agsensorsolutions.com 。前瞻性陳述：本新聞稿包含關於 Datavault AI Inc.（「Datavault AI」、「本公司」、「我們」或「我方」）及其所處產業的「前瞻性陳述」（定義參照《1995 年私人證券訴訟改革法案》（經修訂）及其他證券法規），此類陳述涉及風險與不確定性。此類前瞻性陳述包括但不限於：關於未來事件的陳述、與 AgSensor 建立諮詢合作夥伴關係的預期效益、本公司專有 IDE、DataScore® 及 DataValue® 平台透過基於區塊鏈的代幣化來數位化農業部門所有權權益的預期適用性，以及本公司商業策略的預期營運、技術與商業成果，還有數位資產相關法規變動的預估方向與市場影響。實際結果可能因各種風險與不確定性而與這些前瞻性陳述所指稱的結果存在重大差異，包括但不限於以下事項：本公司與 AgSensor 識別、評估及將農業數據資產代幣化的能力； 本公司專有 IDE、DataScore® 及 DataValue® 平台的部署表現、時程或成功與否；市場對 Datavault AI 服務及產品需求的變化；經濟、市場或監管環境的變化；與代幣化資產相關且不斷演變的監管框架所衍生的風險； 與技術開發及整合相關的風險；以及 Datavault AI 向美國證券交易委員會（SEC）提交的文件中更詳盡描述的其他風險與不確定性，包括截至 2025 年 12 月 31 日止年度的 10-K 表格年度報告，以及 Datavault AI 不時向 SEC 提交的其他文件，該等文件可於 SEC 網站 www.sec.gov 查閱。本新聞稿中所作的前瞻性陳述僅涉及該陳述作出當日的事件。Datavault AI 概無義務更新本新聞稿中的任何前瞻性陳述，以反映本新聞稿日期之後的事件或情況，或反映新資訊或意外事件的發生，但法律另有規定者除外。Datavault AI 未必能實際實現其前瞻性陳述中所披露的計劃、意圖或預期，您不應過度依賴此類前瞻性陳述。Datavault AI 的前瞻性陳述並未反映其未來可能進行的任何收購、合併、處分、合資企業或投資所帶來的潛在影響。媒體聯絡人marketing@dvlt.ai 投資人聯絡人Edward Barger投資人關係副總裁ir@dvlt.ai ebarger@dvlt.ai 消息來源：Datavault AI Inc Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAMPA, FLA., Apr 14, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech's wholly owned subsidiary, Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs.The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations' technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx's digital hub, the combined platform is positioned to streamline the prescription journey from intake through fulfillment.Prashant Patel, Chief Executive Officer of Wellgistics Health, commented, "This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies. By combining KareRx's provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively."The joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than 200,000 patient lives based on third-party internal estimates.Mital Panera, Founder and Chief Executive Officer of KareRx, added, "KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics' technology stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders and facilitate access to therapies across participating networks."The collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence, and deliver enhanced visibility into patient access and program performance.The joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.About Kare PharmTech, LLCKare Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical ‘lite' branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market unique specialty pharmaceutical ‘lite' products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.Forward-Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛羅里達州坦帕市, 2026年4月14日 - (亞太商訊 via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) （「Wellgistics」或「本公司」），一家領先的醫療保健科技與藥品分銷公司，今日宣布與 Kare PharmTech 的全資子公司 Kare Rx Hub, LLC（「KareRx」）簽署最終合資協議。KareRx 是一家以人工智慧（AI）為驅動的數位樞紐，致力於支援零售藥房、遠距醫療及特殊藥品計畫。此次合資協議的簽署，正式確立了先前公佈的非約束性意向書，標誌著雙方將技術平台與營運團隊整合為統一生態系統的重要里程碑，旨在加速患者獲取治療並提升藥品商業化的效率。透過將 Wellgistics Hub 技術堆疊（包含專有平台 EinsteinRx™ 及 HubRx AI™）與 KareRx 的數位樞紐整合，合併後的平台將能簡化從處方接收至履約的整個流程。Wellgistics Health 執行長 Prashant Patel 表示：「此合資企業體現了我們持續致力於打造一個整合式、技術驅動的平台，以改善處方流程各環節的協調性，並協助患者取得治療。透過結合 KareRx 的醫療提供者連結與數位互動能力，以及我們的基礎設施，我們相信此合作將提升營運效率，並協助製藥商及其他醫療保健利害關係人更有效地規劃用藥途徑。」該合資企業整合了雙方組織的臨床、營運及商業團隊，使醫療提供者、藥房與患者之間能更無縫地協調合作。透過此次整合，該平台強化了多項關鍵功能，包括資格與福利核驗、事前授權工作流程、處方箋路由，以及直接向患者配送服務。整合後的生態系統涵蓋日益擴大的全國性獨立藥房網絡、醫療服務提供者網絡及遠距醫療管道，根據第三方內部估算，其服務範圍可觸及超過 20 萬名患者。KareRx 創辦人暨執行長 Mital Panera 補充道：「KareRx 的創立初衷，是透過科技驅動的解決方案串聯醫療服務提供者、藥局與患者。這家合資企業讓我們得以運用 Wellgistics 的技術架構、製藥專業知識及營運基礎設施，進一步擴展這些能力。我們相信，整合後的平台將有助於強化各利益相關方之間的連結，並促進參與網路內治療方案的可及性。」此次合作進一步強化了「直接面向患者」（DTP）及去中心化照護模式，為製藥商提供一個將治療可及性、可負擔性與處方履行整合為單一解決方案的全面平台。透過運用人工智慧驅動的洞察力與完全整合的營運骨幹，該合資企業旨在降低治療啟動的門檻、提升用藥依從性，並對患者的治療可及性及計畫成效提供更清晰的掌握。該合資企業仍須遵循慣例的實施步驟，且無法保證營運整合的時間表或範圍，亦無法保證預期效益能否實現。有關合資協議的更多詳情，將於本公司向美國證券交易委員會提交的 8-K 表格當前報告中提供。關於 Wellgistics Health, Inc.Wellgistics Health（納斯達克代碼：WGRX）是健康資訊科技領域的領導者，將其專有的藥房調劑優化人工智慧平台 EinsteinRx™ 整合至其獲得專利的區塊鏈智慧合約平台 PharmacyChain™ 中，以優化處方藥調劑流程。該整合平台串聯了 6,500 多家藥局（「Wellgistics 藥局網絡」）及 200 多家製造商，提供批發分銷、數位處方箋傳輸、直接送達患者，以及由人工智慧驅動的樞紐服務，例如資格審核、用藥遵從性管理、新用戶註冊、事前授權，以及依需求提供的現金支付履約服務，以優化患者的用藥可及性。Wellgistics 提供端到端解決方案，旨在為美國獨立藥房恢復處方藥市場的獲取管道、透明度及信任。關於 Kare PharmTech, LLCKare Rx Hub 是一個基於人工智慧（AI）的數位樞紐，服務對象涵蓋零售藥局、遠距醫療入口網站，以及特殊藥品「輕量版」品牌產品，擁有超過 500 家醫師合作夥伴關係，以及 200 家推廣獨特特殊藥品「輕量版」產品的獨立藥局合作夥伴。Kare Rx Hub 由 Kare Pharmtech, LLC 擁有，該公司由 Kiran Patel 博士掌控。Patel 博士於 1992 年創立了 Medicaid 服務供應商 WellCare，並於 2002 年以 2 億美元售出。2007 年，Patel 博士創立了 America's 1st Choice Holdings，並收購了 Freedom Health 和 Optimum Holdings。2017年，他將 America's 1st Choice Holdings 出售予 Anthem, Inc.。Patel 博士是一位知名慈善家，曾獲《佛羅里達趨勢》雜誌評選為「年度佛羅里達人」。前瞻性陳述本新聞稿可能包含前瞻性陳述。前瞻性陳述包括有關計劃、目標、策略、未來事件或表現的陳述，以及相關假設和其他非歷史事實的陳述。當 Wellgistics Health 使用「可能」、「將」、「打算」、「應」、「相信」、「預期」、「預料」、「預測」、「估計」或類似表述，且該等表述並非僅涉及歷史事項時，即構成前瞻性陳述。這些前瞻性陳述包括但不限於關於 Wellgistics Health 策略的陳述，以及對其未來營運、前景與計畫的描述。前瞻性陳述並非對未來表現的保證，且涉及可能導致實際結果產生重大差異的風險與不確定性。其他相關因素已於 Wellgistics Health 向美國證券交易委員會（SEC）提交的文件中詳述，該文件可於 www.sec.gov 查閱。Wellgistics 媒體與投資者聯絡資訊媒體：media@wellgisticshealth.com投資者關係：IR@wellgisticshealth.com消息來源：Wellgistics Health, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Apr 14, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), announces the launch of Field X Fashion, Issue 3, the global brand's annual magazine, presented this year as a special 135th Anniversary edition. Available worldwide in both digital and coffee-table print formats, the latest 48-page issue offers a dynamic look at the brand's continued global growth and milestone achievements throughout 2025. This publication will be enjoyed by millions of U.S. Polo Assn. sports fans and consumers across 190 countries worldwide.1. U.S. Polo Assn.'s third issue of Field X Fashion - 135th Anniversary Special Edition Cover2. U.S. Polo Assn. is the Official Sports Brand of the United States Polo Association, Field X Fashion page 43. U.S. Polo Assn. Spring 2026 Global Collection, Field X Fashion page 7Field X Fashion, Issue 3 captures the momentum of U.S. Polo Assn.'s 135th Anniversary of sport inspiration from the USPA, founded in 1890, bringing together the most compelling stories from across the brand's international footprint. This special edition also highlights global sporting events, fashion collections and campaigns, philanthropic initiatives, sustainability milestones, retail expansion, and key partnerships that define the brand's presence around the world.As a storytelling platform, Field X Fashion continues to connect U.S. Polo Assn.'s sport-inspired heritage with its modern, global lifestyle identity. The 135th Anniversary Special Edition reflects a year of elevated visibility, meaningful impact, and continued engagement with millions of consumers, sports fans, and partners worldwide. The magazine also provides a look into the brand's newest global polo shirt campaign, An Icon Born from the Game™."Field X Fashion continues to be an important way for U.S. Polo Assn. to share our brand story with audiences around the world," said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar U.S. Polo Assn. brand. "This special 135th Anniversary Edition captures the incredible momentum of our brand, from global sport and fashion to our sustainability journey, while celebrating the athletes, partners, and consumers who have helped shape our legacy over the past 135 years.""Field X Fashion also offers a sneak peek into our Spring 2026 Global Campaign, The Polo Shirt:An Icon Born from the Game, which is a powerful tribute to the legendary polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials," added Prince.Since its 2023 debut, Field X Fashion has evolved into a global content platform designed to engage and inspire the brand's growing sport and fashion audience. The publication continues to receive industry recognition by remaining focused on delivering authentic, engaging storytelling that reflects the breadth and depth of the U.S. Polo Assn. brand worldwide.Customers, sports fans, influencers, and partners around the world can now experience the digital version of Field X Fashion, Issue 3 on uspoloassnglobal.com. Print issues will be distributed nationwide at select U.S. Polo Assn. stores, showrooms, and global events. U.S. Polo Assn. remains committed to building on this annual tradition, offering fresh perspectives on sport, fashion, and global brand impact with each new edition.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sport content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.For Additional Information, Contact:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +001.561.790.8036 - E-mail: skovalsky@uspagl.comKaela Drake - Senior PR & Communications SpecialistPhone +001.561.530.5300 - E-mail: kdrake@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛羅里達州西棕櫚灘, 2026年4月14日 - (亞太商訊 via SeaPRwire.com) - 美國馬球協會（USPA）的官方運動品牌 U.S. Polo Assn. 宣布推出《Field X Fashion》第三期，這本全球性品牌的年度雜誌今年以慶祝成立 135 週年的特別紀念版形式呈現。本期共48頁，以數位版及精裝印刷版形式在全球發行，生動呈現了品牌在2025年持續的全球成長與里程碑式成就。這本刊物將讓全球190個國家數百萬名U.S. Polo Assn.運動愛好者與消費者盡享閱讀樂趣。1. U.S. Polo Assn.《Field X Fashion》第三期——135週年紀念特刊封面2. U.S. Polo Assn. 是美國馬球協會的官方運動品牌，《Field X Fashion》第 4 頁3. U.S. Polo Assn. 2026 春季全球系列，Field X Fashion 第 7 頁《Field X Fashion》第三期捕捉了 U.S. Polo Assn. 創立 135 週年的運動靈感動能，該品牌源自 1890 年成立的美國馬球協會（USPA），並匯集了品牌在全球各地最引人入勝的故事。這期特刊亦重點呈現了全球體育賽事、時尚系列與宣傳活動、慈善計劃、永續發展里程碑、零售擴張，以及定義品牌全球影響力的關鍵合作夥伴關係。作為一個敘事平台，《Field X Fashion》持續將 U.S. Polo Assn. 源自運動的傳承，與其現代化的全球生活風格形象相連結。這本 135 週年紀念特刊，反映了過去一年品牌在提升能見度、創造深遠影響，以及持續與全球數百萬消費者、運動迷及合作夥伴互動方面的成果。本雜誌同時也深入介紹了品牌最新的全球馬球衫宣傳活動——「An Icon Born from the Game™」。「《Field X Fashion》始終是 U.S. Polo Assn. 向全球受眾傳遞品牌故事的重要媒介，」負責管理這個市值數十億美元品牌的 USPA Global 總裁兼執行長 J. Michael Prince 表示。「這本135週年紀念特刊不僅展現了我們品牌從全球運動與時尚領域到永續發展之路的非凡動能，更向過去135年來共同塑造我們傳奇的運動員、合作夥伴及消費者致敬。」「《Field X Fashion》同時也搶先揭曉了我們2026年春季全球廣告活動《馬球衫：源自賽場的經典》，這是一場對傳奇馬球衫純正運動起源及其演變為全球最歷久彌新的時尚單品之一所獻上的深情致敬，」普林斯補充道。自2023年首刊問世以來，《Field X Fashion》已發展成為一個全球內容平台，旨在吸引並激勵品牌日益壯大的運動與時尚受眾。該刊物持續專注於呈現真實且引人入勝的故事，展現U.S. Polo Assn.品牌在全球的廣度與深度，因而持續獲得業界認可。全球的顧客、運動迷、意見領袖及合作夥伴，現可於 uspoloassnglobal.com 瀏覽《Field X Fashion》第三期的數位版。紙本刊物將於全美精選的 U.S. Polo Assn. 門市、展示廳及全球活動中發行。U.S. Polo Assn. 將持續秉持這項年度傳統，透過每一期新刊，為運動、時尚及全球品牌影響力帶來嶄新視角。關於 U.S. Polo Assn. 及 USPA GlobalU.S. Polo Assn. 是美國馬球協會（USPA）的官方運動品牌，該協會成立於 1890 年，是美國規模最大的馬球俱樂部及馬球運動員組織。憑藉數十億美元的全球業務規模，以及透過超過 1,200 家 U.S. Polo Assn. 零售店和數千個其他銷售據點的全球分銷網絡，U.S. Polo Assn. 在全球 190 多個國家為男女及兒童提供服飾、配件和鞋類產品。該品牌贊助全球各大馬球賽事，包括每年於棕櫚灘的 NPC 舉辦的「美國公開馬球錦標賽®」（U.S. Open Polo Championship®），此為美國首屈一指的馬球錦標賽。透過與美國 ESPN、歐洲 TNT 和 Eurosport 以及印度 Star Sports 的歷史性合作協議，由 U.S. Polo Assn. 贊助的多項世界頂級馬球錦標賽現已透過電視轉播，讓全球數百萬體育迷首次得以親睹這項令人熱血沸騰的運動。根據《License Global》的報導，U.S. Polo Assn. 一直與 NFL、PGA 巡迴賽和一級方程式賽車並列為全球頂尖的體育授權商之一。此外，這個受運動啟發的品牌因全球業務拓展及體育內容而屢獲國際獎項肯定。憑藉其作為全球品牌的巨大成功，U.S. Polo Assn. 曾獲《富比世》、《財星》、《現代零售》及《GQ》等媒體報導，並登上雅虎財經與彭博社等全球眾多知名媒體平台。欲了解更多資訊，請造訪 uspoloassnglobal.com 並追蹤 @uspoloassn。USPA Global 是美國馬球協會（USPA）的子公司，負責管理市值數十億美元的運動品牌 U.S. Polo Assn.。USPA Global 同時管理其子公司 Global Polo，該公司是全球馬球運動內容的領導者。欲了解更多資訊，請造訪 globalpolo.com 或 YouTube 上的 Global Polo 頻道。如需更多資訊，請聯絡：Stacey Kovalsky - VP, Global PR and CommunicationsPhone +001.561.790.8036 - E-mail: skovalsky@uspagl.comKaela Drake - Senior PR & Communications SpecialistPhone +001.561.530.5300 - E-mail: kdrake@uspagl.com來源：U.S. Polo Assn. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com